Anti-CD36 antibodies and uses thereof
Anti-CD36 antibodies target CD36 functions to inhibit immunosuppressive and metastatic processes, reducing tumor growth and enhancing immune responses in cancer treatment.
Patent Information
- Application Number
- CN202380036702.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-07
- Filing Date
- 2023-03-06
- Publication Date
- 2024-12-06
AI Technical Summary
CD36-mediated processes contribute to immunosuppression, angiogenesis, and metastasis in cancer, with existing treatments lacking effective targeting mechanisms.
Development of anti-CD36 antibodies that bind with high affinity to inhibit or block CD36 functions, including fatty acid transport and immunomodulatory effects, thereby targeting tumor-associated macrophages, MDSCs, regulatory T cells, and CD8 T cells.
The antibodies effectively reduce tumor growth and metastasis by inhibiting CD36-dependent pathways, enhancing immune responses against cancer cells.
Smart Images

Figure CN119095872A_ABST
Abstract
Description
[0001] This application claims priority to U.S. Provisional Patent Application No. 63 / 317,160, filed on March 7, 2022, the entire contents of which are incorporated herein by reference. Technical Field
[0002] The present disclosure relates to antibodies that bind to CD36 and methods of using such antibodies.
[0003] References to sequence listings
[0004] An official copy of the sequence listing is submitted with the specification in an XML file in WIPO standard ST.26 format, with the file name "09793-005WO1.xml", the creation date of February 26, 2023, and the size of 75,330 bytes. The sequence listing submitted through the USPTO Patent Center is part of the specification, and its entire content is incorporated herein by reference. Background Art
[0005] Macrophages and other myeloid cells play a prominent role in creating and maintaining the immunosuppressive environment of tumors, and different microenvironments exist in which tumor-associated macrophages (TAMs) suppress immune responses and promote other processes, including angiogenesis, cancer cell migration, and metastasis (Lewis & Pollard, 2006; Pollard, 2008; Wu et al., 2020). About two decades ago, for example, vascular endothelial growth factor produced by TAMs was proposed to play a role in lymphatic metastasis of several human cancers (e.g., Pepper et al., 2003), and in 2006, it was demonstrated that clodronate liposome-mediated depletion of TAMs inhibited tumor growth in experimental models via mechanisms that are thought to include reduced tumor angiogenesis (Zeisberger et al., 2006). In addition, macrophages not only promote tumor cell egress from primary tumors, but are also thought to contribute to seeding at distant metastatic sites (Joyce & Pollard, 2009; Psaila & Lyden, 2009).
[0006] While the understanding of the various pro-tumorigenic (commonly referred to as M2) and anti-tumorigenic M1 macrophages and other myeloid cells is still evolving (e.g., see Wu et al., 2020), it has long been recognized that high TAM numbers are associated with reduced patient survival (with only a few notable exceptions) and are an independent prognostic factor in many cancers (Lewis & Pollard, 2006). In addition, myeloid cells called myeloid-derived suppressor cells (MDSC) have been found in the peripheral blood and tumor tissue of cancer patients, and depletion or other targeting of MDSC in mouse models leads to improved immune responses and delayed tumor growth (Goedegebuure et al., 2011). MDSC are said to have some heterogeneity but are still described as belonging to monocyte and granulocyte subsets with different immunosuppressive mechanisms. Among other roles, tumor MDSC have been involved in the recruitment and maintenance of immunosuppressive regulatory T cells and in promoting angiogenesis and metastasis (Goedegebuure et al., 2011; Oh et al., 2013). Like MDSCs, at least as we now know them, a subset of human peripheral blood cells that are CD45 positive but CD14 negative were described by Barrett et al. (2007) as expressing CD36 and the immunosuppressive cytokine interleukin-10.
[0007] CD36 is a transmembrane cell surface protein that has been called, among other names, platelet glycoprotein 4, fatty acid translocase (FAT), and scavenger receptor class B member 3 (SCARB3). CD36 binds and transports fatty acids into cells, but also binds a large number of other ligands, such as apoptotic cells, low-density lipoproteins, phospholipids and their oxidized forms (Pepino et al., 2014; Wang & Li, 2019). CD36 also has a separate thrombospondin binding domain (Pepino et al., 2014; Wang & Li, 2019). Both of these different functional events, thrombospondin binding to fatty acids, can lead to a variety of downstream signaling events that may differ depending on the cell type and the various other CD36 and / or ligand interaction partners (Pepino et al., 2014; Wang & Li, 2019). Fatty acid transport by CD36 is involved in the metabolic “wiring” of various cells if it is not required for cell differentiation state or survival. For example, fatty acid transport by CD36 has been shown to be required for M2 macrophage differentiation via a mechanism associated with the level or state of endoplasmic reticulum stress (Oh et al., 2012).
[0008] CD36 has also been shown to be essential for M2 macrophage activation, as measured by markers of immunosuppressive capacity such as PDL-2 expression (Huang et al., 2014). CD36-mediated lipid transport has also been implicated in the acquisition of immunosuppressive effectors during MDSC differentiation (Al-Khami et al., 2017). When compared to tumor-bearing wild-type mice, CD36-deficient mice had reduced numbers of tumor-resident MDSCs in all (lung and colon) tumor models tested, and this was reflected in tumors of wild-type chimeric mice that were CD36-deficient in their bone marrow (Al-Khami et al., 2017). It has recently been demonstrated that TAMs in melanoma and myeloma models of CD36-deficient mice were significantly reduced compared to those of wild-type mice, and that such TAMs of wild-type mice had elevated CD36 expression and lipid accumulation compared to normal macrophages (Su et al., 2020).
[0009] Given the importance of CD36-mediated uptake of fatty acids or other ligands for M2 TAM and MDSC biology, it could be expected that blocking CD36 ligand transport would reduce tumor growth by leading to reduced immunosuppressive capacity, angiogenesis, and / or metastasis, which would otherwise be promoted by M2 TAM and MDSC. Indeed, mouse tumor models have shown that mice lacking CD36 have significantly reduced tumor growth (lung and colon) and that this is due to the loss of CD36 in bone marrow-derived cells (Al-Khami et al., 2017).
[0010] In addition to myeloid cells, it has recently been reported that CD36 is expressed on certain tumor-resident regulatory T cells and that blocking CD36 with antibodies that block CD36-mediated fatty acid transport leads to a reduction in melanoma growth in experimental models (Wang et al., 2020). Furthermore, it has been demonstrated that CD36 deficiency on mouse regulatory T cells alone is sufficient to cause a reduction in melanoma growth (Wang et al., 2020). Recently, CD36 expression by tumor-resident CD8 T cells has been shown to impair their antitumor capacity and lead to increased tumor CD8 T cell death via lipid peroxidation leading to ferroptosis (Ma et al., 2021). A previous report also described CD36 on tumor-infiltrating CD8 T cells and its adverse consequences for such CD8 T cells (Xu et al., 2020), and this report was later published in a peer-reviewed format (Xu et al., 2021).
[0011] There are also many reports on the role of ligand transport through CD36 expressed on tumor cells. For example, CD36 is involved in tamoxifen resistance in breast cancer (Liang et al., 2018), chemotherapy resistance in melanoma (Alioa et al., 2019), and resistance to HER2 targeted therapy in lung cancer (Feng et al., 2019). As early as 1993, CD36 was found to be associated with doxorubicin resistance in the screening of doxorubicin-resistant sublines of the human myeloid leukemia line K562, although overexpression of CD36 in the doxorubicin-sensitive parental cell line itself did not confer doxorubicin resistance (Sugimoto et al., 1993). CD36 has also been implicated in increased self-renewal, survival, and / or proliferation of glioblastoma (Hale et al., 2014) and leukemia (Ye et al., 2016) stem cells. In other words, CD36 appears to be involved in chemotherapy resistance through leukemia stem cells in the adipose tissue microenvironment (Ye et al., 2016). When CD36 was “knocked down” in stem cells by RNA interference, glioblastoma formation using patient-derived glioblastoma stem cells in a xenograft mouse model was significantly reduced, and the proliferation of glioblastoma stem cells was increased in a CD36-dependent manner by exposure to oxidized low-density lipoprotein (Hale et al., 2014). CD36 has also been shown to be an informative biomarker for brain malignancies and negatively correlated with patient prognosis (Hale et al., 2014).
[0012] Recently, CD36 was shown to be important for prostate cancer progression and tumor growth in mouse models, and reducing CD36 expression in prostate cancer cells by RNA interference or other approaches using antibodies to block CD36-mediated lipid transport resulted in reduced cell migration ability and tumor growth in mouse models (Watt et al., 2019).
[0013] CD36 has also been proposed as a prognostic metastatic biomarker for various cancers (Enciu et al., 2018), and has been shown to promote metastasis of oral squamous cell carcinoma (OSCC) cells, breast cancer cells, and melanoma cells in mouse models (PCT / EP2016 / 073208; Pascual et al., 2017). OSCC metastasis was observed after cell injection into the orthotopic site (tongue), and was reduced by antibodies that blocked fatty acid transport through CD36. Melanoma and breast cancer cells were injected into the blood of mice so that they could potentially colonize the metastatic microenvironment, and this metastasis was reduced when such cells were used in which CD36 was "knocked out" by RNA interference (PCT / EP2016 / 073208; Pascual et al., 2017). As mentioned above, CD36 is also expected to be involved in the invasion of tumor cells from the primary tumor site into the lymphatic and / or blood circulation, primarily through its role in the myeloid cells of the immune system. Fatty acid transport via CD36 on HCC cells has also been shown to result in an increase in epithelial-mesenchymal transition, whereas chemical inhibition of CD36-mediated fatty acid transport reduced this phenotype as well as HCC cell migration (Nath et al., 2015).
[0014] All of the above paints a picture in which fatty acids or other ligands transported into cells via CD36 are involved in metabolic adaptation or differentiation of various cell types, but it should also be emphasized that CD36 signaling can lead to more direct immunosuppressive effects. Some of these have been mentioned above, but it should be emphasized that it has been proposed that apoptotic cell binding via CD36 generally promotes steady-state anti-inflammatory processes, and apoptotic cell binding via CD36 at least partially leads to the production of IL-10 by macrophages after apoptotic cell binding (as well as other immunosuppressive effects on macrophages) (Chung et al., 2007). CD36-mediated ligand transport may also lead to the production of immunosuppressive metabolites. That is, due to the increase in the production of arachidonic acid caused by intracellular signaling induced by CD36 ligands, substrates are provided for the production of prostaglandins (e.g., Kuda et al., 2011), some of which are known to have a wide range of immunomodulatory effects (e.g., see Wang and Dubois, 2006; Mizuno et al., 2019). Of course, immunosuppressive prostaglandin E2 is produced in many cancers by tumor cells as well as immune system cells, including myeloid cells and others (Wang and Dubois, 2006; Mizuno et al., 2019), such as inducible regulatory T cells (Whiteside and Jackson, 2013). In addition, at least mouse macrophages have been shown to produce prostaglandin E2 in a CD36-dependent manner, although this is not the case in cancer models (Almeida et al., 2014).
[0015] In addition to the many roles of CD36 in cancer, CD36 ligand trafficking clearly plays a prominent pathological role in foam cell formation in atherosclerosis (e.g., Zhao et al., 2018), nonalcoholic fatty liver disease (e.g., Rada et al., 2020), and other conditions. Therefore, antibodies that can block apoptotic cell or other ligand binding / trafficking via CD36 have several potential applications. Summary of the invention
[0016] The present disclosure provides anti-CD36 antibodies that specifically bind to human CD36 with high affinity. The antibodies are capable of reducing, inhibiting and / or completely blocking immunomodulatory effects mediated by CD36, including CD36-mediated fatty acid transport (e.g., cellular uptake of oxidized low-density lipoprotein or "oxLDL").
[0017] In at least one embodiment, the present disclosure provides an anti-CD36 antibody comprising (i) a first light chain complementary determining region (CDR-L1), a second light chain complementary determining region (CDR-L2), and a third light chain complementary determining region (CDR-L3), and / or (ii) a first heavy chain complementary determining region (CDR-H1), a second heavy chain complementary determining region (CDR-H2), and a third heavy chain complementary determining region (CDR-H3), wherein:
[0018] (a) CDR-H1 comprises the amino acid sequence of SEQ ID NO: 3, 21, 24 or 27;
[0019] (b) CDR-H2 comprises the amino acid sequence of SEQ ID NO: 4, 28, 31, 34, 37, 40 or 43;
[0020] (c) CDR-H3 comprises the amino acid sequence of SEQ ID NO: 5;
[0021] (d) CDR-L1 comprises an amino acid sequence selected from SEQ ID NO: 7;
[0022] (e) CDR-L2 comprises an amino acid sequence selected from SEQ ID NO: 8, 12 or 15; and
[0023] (f) CDR-L3 comprises an amino acid sequence selected from SEQ ID NO: 9, 13 or 18.
[0024] In at least one embodiment of the anti-CD36 antibody of the present disclosure:
[0025] (a) CDR-H1 comprises the amino acid sequence of SEQ ID NO: 3, CDR-H2 comprises the amino acid sequence of SEQ ID NO: 4, CDR-H3 comprises the amino acid sequence of SEQ ID NO: 5, CDR-L1 comprises the amino acid sequence of SEQ ID NO: 7, CDR-L2 comprises the amino acid sequence of SEQ ID NO: 8, and CDR-L3 comprises the amino acid sequence of SEQ ID NO: 9;
[0026] (b) CDR-H1 comprises the amino acid sequence of SEQ ID NO:3, CDR-H2 comprises the amino acid sequence of SEQ ID NO:4, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:12, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:13;
[0027] (c) CDR-H1 comprises the amino acid sequence of SEQ ID NO:3, CDR-H2 comprises the amino acid sequence of SEQ ID NO:4, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:13;
[0028] (d) CDR-H1 comprises the amino acid sequence of SEQ ID NO:3, CDR-H2 comprises the amino acid sequence of SEQ ID NO:4, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18;
[0029] (e) CDR-H1 comprises the amino acid sequence of SEQ ID NO:21, CDR-H2 comprises the amino acid sequence of SEQ ID NO:4, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18;
[0030] (f) CDR-H1 comprises the amino acid sequence of SEQ ID NO:24, CDR-H2 comprises the amino acid sequence of SEQ ID NO:4, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18;
[0031] (g) CDR-H1 comprises the amino acid sequence of SEQ ID NO:27, CDR-H2 comprises the amino acid sequence of SEQ ID NO:28, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18;
[0032] (h) CDR-H1 comprises the amino acid sequence of SEQ ID NO:3, CDR-H2 comprises the amino acid sequence of SEQ ID NO:31, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18;
[0033] (i) CDR-H1 comprises the amino acid sequence of SEQ ID NO:3, CDR-H2 comprises the amino acid sequence of SEQ ID NO:34, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18;
[0034] (j) CDR-H1 comprises the amino acid sequence of SEQ ID NO:3, CDR-H2 comprises the amino acid sequence of SEQ ID NO:37, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18;
[0035] (k) CDR-H1 comprises the amino acid sequence of SEQ ID NO:3, CDR-H2 comprises the amino acid sequence of SEQ ID NO:40, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18; or
[0036] (l) CDR-H1 comprises the amino acid sequence of SEQ ID NO:24, CDR-H2 comprises the amino acid sequence of SEQ ID NO:43, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18.
[0037] In at least one embodiment, the present disclosure provides an anti-CD36 antibody comprising: (i) a first heavy chain complementary determining region (CDR-H1), a second heavy chain complementary determining region (CDR-H2), and a third heavy chain complementary determining region (CDR-H3), wherein the sequences of the CDR-H1, CDR-H2, and CDR-H3 are from a VH region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 20, 23, 26, 30, 33, 36, 39, and 42; and (ii) a first light chain complementary determining region (CDR-L1), a second light chain complementary determining region (CDR-L2), and a third light chain complementary determining region (CDR-L3), wherein the sequences of the CDR-L1, CDR-L2, and CDR-L3 are from a VL region having an amino acid sequence selected from the group consisting of SEQ ID NOs: The amino acid sequences of NO:6, 11, 14 and 17; wherein the CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 are numbered according to Kabat.
[0038] In at least one embodiment of the anti-CD36 antibody:
[0039] (a) the VH amino acid sequence is SEQ ID NO: 2 and the VL amino acid sequence is SEQ ID NO: 6;
[0040] (b) the VH amino acid sequence is SEQ ID NO: 2 and the VL amino acid sequence is SEQ ID NO: 11;
[0041] (c) the VH amino acid sequence is SEQ ID NO: 2 and the VL amino acid sequence is SEQ ID NO: 14;
[0042] (d) the VH amino acid sequence is SEQ ID NO: 2 and the VL amino acid sequence is SEQ ID NO: 17;
[0043] (e) the VH amino acid sequence is SEQ ID NO: 20 and the VL amino acid sequence is SEQ ID NO: 17;
[0044] (f) the VH amino acid sequence is SEQ ID NO:23 and the VL amino acid sequence is SEQ ID NO:17;
[0045] (g) the VH amino acid sequence is SEQ ID NO:26 and the VL amino acid sequence is SEQ ID NO:17;
[0046] (h) the VH amino acid sequence is SEQ ID NO:30 and the VL amino acid sequence is SEQ ID NO:17;
[0047] (i) the VH amino acid sequence is SEQ ID NO: 33 and the VL amino acid sequence is SEQ ID NO: 17;
[0048] (j) the VH amino acid sequence is SEQ ID NO:36 and the VL amino acid sequence is SEQ ID NO:17;
[0049] (k) the VH amino acid sequence is SEQ ID NO: 39 and the VL amino acid sequence is SEQ ID NO: 17; or
[0050] (l) The VH amino acid sequence is SEQ ID NO:42 and the VL amino acid sequence is SEQ ID NO:17.
[0051] In at least one embodiment of the anti-CD36 antibodies of the present disclosure, the antibody comprises a heavy chain variable domain (V H ) that is at least 90% identical to a sequence selected from SEQ ID NO: 2, 20, 23, 26, 30, 33, 36, 39 or 42. H ) amino acid sequence; and / or a light chain variable domain (V L ) amino acid sequence.
[0052] In at least one embodiment of the anti-CD36 antibody of the present disclosure:
[0053] (a) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 2 HThe amino acid sequence is at least 90% identical to SEQ ID NO: 6. L Amino acid sequence;
[0054] (b) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 2 H The amino acid sequence is at least 90% identical to SEQ ID NO: 11. L Amino acid sequence;
[0055] (c) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 2 H The amino acid sequence is at least 90% identical to SEQ ID NO: 14. L Amino acid sequence;
[0056] (d) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 2 H The amino acid sequence is at least 90% identical to SEQ ID NO: 17. L Amino acid sequence;
[0057] (e) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 20 H The amino acid sequence is at least 90% identical to SEQ ID NO: 17. L Amino acid sequence;
[0058] (f) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 23 H The amino acid sequence is at least 90% identical to SEQ ID NO: 17. L Amino acid sequence;
[0059] (g) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 26 H The amino acid sequence is at least 90% identical to SEQ ID NO: 17. L Amino acid sequence;
[0060] (h) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 30 H The amino acid sequence is at least 90% identical to SEQ ID NO: 17. L Amino acid sequence;
[0061] (i) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 33 HThe amino acid sequence is at least 90% identical to SEQ ID NO: 17. L Amino acid sequence;
[0062] (j) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 36 H The amino acid sequence is at least 90% identical to SEQ ID NO: 17. L Amino acid sequence;
[0063] (k) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 39 H The amino acid sequence is at least 90% identical to SEQ ID NO: 17. L Amino acid sequence; or
[0064] (l) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 42 H The amino acid sequence is at least 90% identical to SEQ ID NO: 17. L Amino acid sequence.
[0065] In at least one embodiment of the anti-CD36 antibody of the present disclosure, the antibody comprises a heavy chain (HC) amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NO: 44, 48, 50, 51, 52, 53, 54, 55, 56 or 57, and / or a light chain (LC) amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NO: 45, 46, 47 or 49.
[0066] In at least one embodiment of the anti-CD36 antibody of the present disclosure, the antibody comprises:
[0067] (a) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:44 and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:45;
[0068] (b) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:44 and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:46;
[0069] (c) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:44 and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:47;
[0070] (d) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:44, and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49;
[0071] (e) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:48, and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49;
[0072] (f) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:50 and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49;
[0073] (g) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:51 and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49;
[0074] (h) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:52 and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49;
[0075] (i) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:53 and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49;
[0076] (j) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:54 and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49;
[0077] (k) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:55 and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49;
[0078] (l) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:56 and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49; or
[0079] (m) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:57 and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49.
[0080] In at least one embodiment of the anti-CD36 antibody of the present disclosure:
[0081] (a) The antibody was expressed at 1×10-8 M or less, 1×10 -9 M or less, 1×10 -10 M or less binding affinity to human CD36; optionally, wherein the binding affinity is measured by the equilibrium dissociation constant (K) with the hCD36 polypeptide of SEQ ID NO: 58 or 59 D ) to measure;
[0082] (b) The antibody was expressed at 1×10 -8 M or less, 1×10 -9 M or less, 1×10 -10 M or less binding affinity to mouse CD36; optionally, wherein the binding affinity is measured by the equilibrium dissociation constant (K) with the mCD36 polypeptide of SEQ ID NO: 60 or 61 D ) to measure;
[0083] (c) The antibody was expressed at 1×10 -8 M or less, 1×10 -9 M or less, 1×10 -10 M or less binding affinity to rhesus monkey CD36; optionally, wherein the binding affinity is measured by the equilibrium dissociation constant (K) with the rhesus monkey CD36 polypeptide of SEQ ID NO: 62 or 63 D ) to measure;
[0084] (d) the antibody inhibits CD36-dependent oxidized LDL uptake in F293 cells overexpressing surface human CD36 by at least 65%, at least 75%, at least 85%, at least 95% or at least 100%; optionally, wherein at a concentration of oxLDL of 1-10 μg / mL, the antibody has an IC of 5 nM or less, 1 nM or less, 0.5 nM or less, or 0.1 nM or less 50 ;
[0085] (e) the antibody inhibits CD36-dependent oxidized LDL uptake in U937 cells by at least 65%, at least 75%, at least 85%, at least 95% or at least 100%; optionally, wherein at a concentration of oxLDL of 1-10 μg / mL, the antibody has an IC of 5 nM or less, 1 nM or less, 0.5 nM or less, or 0.1 nM or less 50 ; and / or
[0086] (f) the antibody inhibits CD36-dependent oxidized LDL uptake in mouse CD45+ TIL by at least 65%, at least 75%, at least 85%, at least 95% or at least 100%; optionally, wherein at a concentration of oxLDL of 1-10 μg / mL, the antibody has an IC of 5 nM or less, 1 nM or less, 0.5 nM or less, or 0.1 nM or less 50 .
[0087] The present disclosure also provides embodiments of the anti-CD36 antibodies disclosed herein, which include embodiments wherein: (i) the antibody is a human antibody, a humanized antibody or a chimeric antibody; (ii) the antibody comprises a fusion with a protein; optionally, a fusion with an immunostimulatory cytokine (e.g., IL-2, IL-7, IL-10, IL-12, IL-15, IL-21 or IFN-α); (iii) the antibody is a full-length antibody of the IgG class, optionally, wherein the IgG class antibody has a fusion protein selected from IgG1, IgG2, IgG3 and Ig G4 isotype; (iv) the antibody comprises an Fc region variant, optionally, an Fc region variant that changes effector function and / or a variant that changes antibody half-life; (v) the antibody is an antibody fragment, optionally, selected from the group consisting of F(ab')2, Fab', Fab, Fv, single domain antibody (VHH) and scFv; (vi) the antibody comprises an immunoconjugate, optionally, wherein the immunoconjugate comprises a therapeutic agent for treating a CD36-mediated disease or condition; or (vii) the antibody is a multispecific antibody; optionally, a bispecific antibody.
[0088] In at least one embodiment, the present disclosure provides an isolated polynucleotide or a vector comprising a polynucleotide, wherein the sequence of the polynucleotide encodes an anti-CD36 antibody of the present disclosure or a polypeptide chain of an anti-CD36 antibody of the present disclosure. In at least one embodiment, the isolated polynucleotide or vector comprises a sequence encoding a polypeptide of an anti-CD36 antibody of the present disclosure. In at least one embodiment of the isolated polynucleotide or vector, the encoded polypeptide chain has an amino acid sequence comprising:
[0089] (a) CDR-H1 comprises the amino acid sequence of SEQ ID NO: 3, 21, 24 or 27; CDR-H2 comprises the amino acid sequence of SEQ ID NO: 4, 28, 31, 34, 37, 40 or 43; and CDR-H3 comprises the amino acid sequence of SEQ ID NO: 5;
[0090] (b) CDR-L1 comprises an amino acid sequence selected from SEQ ID NO: 7; CDR-L2 comprises an amino acid sequence selected from SEQ ID NO: 8, 12 or 15; and CDR-L3 comprises an amino acid sequence selected from SEQ ID NO: 9, 13 or 18;
[0091] (c) a heavy chain variable domain (V) having at least 90% identity to a sequence selected from SEQ ID NO: 2, 20, 23, 26, 30, 33, 36, 39 or 42. H ) amino acid sequence;
[0092] (d) a light chain variable domain (V) having at least 90% identity to a sequence selected from SEQ ID NO: 6, 11, 14 or 17 L ) amino acid sequence;
[0093] (e) a heavy chain (HC) amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NO: 44, 48, 50, 51, 52, 53, 54, 55, 56 or 57; and / or
[0094] (f) a light chain (LC) amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NO: 45, 46, 47 or 49.
[0095] In at least one embodiment, the present disclosure also provides an isolated host cell comprising a polynucleotide or vector encoding an anti-CD36 antibody or a polypeptide chain of an anti-CD36 antibody of the present disclosure. In at least one embodiment, the present disclosure also provides a method for producing an anti-CD36 antibody of the present disclosure, comprising culturing a host cell comprising a polynucleotide or vector encoding an anti-CD36 antibody, thereby producing the antibody.
[0096] In at least one embodiment, the present disclosure provides a pharmaceutical composition comprising the anti-CD36 antibody of the present disclosure and a pharmaceutically acceptable carrier; optionally, wherein the composition further comprises a chemotherapeutic agent, and / or an antibody specific to an immune checkpoint molecule.
[0097] In at least one embodiment, the present disclosure provides a method of treating a CD36-mediated disease in a subject, the method comprising administering to the subject a therapeutically effective amount of an anti-CD36 antibody of the present disclosure, or administering to the subject a therapeutically effective amount of a pharmaceutical composition of the present disclosure; optionally, wherein the disease is cancer; optionally, wherein the cancer is selected from colon cancer, pancreatic cancer, ovarian cancer, HCC, renal cancer, breast cancer, lung cancer, gastric cancer, melanoma, head and neck cancer, or oral cancer.
[0098] In at least one embodiment, the present disclosure provides a method for treating cancer in a subject, comprising administering to the subject a CD36 antagonist and a chemotherapeutic agent, and / or an antibody specific for an immune checkpoint molecule; optionally, wherein the CD36 antagonist comprises an anti-CD36 antibody, shRNA, siRNA, miRNA, a small molecule inhibitor of CD36, or a combination thereof. BRIEF DESCRIPTION OF THE DRAWINGS
[0099] A better understanding of the novel features and advantages of the present disclosure will be obtained by referring to the following detailed description, which sets forth illustrative embodiments utilizing the principles of the present disclosure, and the accompanying drawings (also referred to herein as "Figures"), wherein:
[0100] Figure 1A , Figure 1B , Figure 1C and Figure 1D Depicted are exemplary anti-CD36 antibodies (12P109, A8A) of the present disclosure in full-length human IgG1 format with recombinant human CD36.ECD ( Figure 1A , Figure 1C ) or mouse CD36.ECD ( Figure 1B , Figure 1D ) ELISA results of binding. ELISA was performed as described in Example 1.
[0101] Figure 2A , Figure 2B , Figure 2C , Figure 2D , Figure 2E and Figure 2F Depicted are ELISA results for binding of exemplary anti-CD36 antibodies of the present disclosure (12P109 and 117 variants) to recombinant human CD36.ECD. The ELISA was performed as described in Example 1.
[0102] Figure 3A , Figure 3B , Figure 3C , Figure 3D 3E depicts a graph showing the results from SEC-UPLC analysis of anti-CD36 antibodies (12P109, A8A and 117 variants) as described in Example 1.
[0103] Figure 4A , Figure 4B , Figure 4C , Figure 4D , Figure 4E and Figure 4F Depicted are graphs showing the interactions of exemplary anti-CD36 antibodies of the present disclosure (117 variants) with overexpressed human CD36 ("hCD36") ( Figure 4A and Figure 4B)、rhesus monkey CD36( Figure 4C and Figure 4D ) or mouse CD36 ("mCD36") ( Figure 4E and Figure 4F ) is a graph showing the results of a cell surface binding assay performed on stable F293 cells, as described in Example 2.
[0104] Figure 5A and Figure 5B Depicts a graph of extracted flow cytometry data showing the effectiveness of anti-CD36 antibodies of the present disclosure in blocking oxLDL binding to U937 cells ( Figure 5A ) and oxLDL uptake ( Figure 5B ) as described in Example 3.
[0105] Fig. 6A , Figure 6B and Figure 6C Depicted are graphs extracted from flow cytometry data illustrating the oxLDL uptake blocking activity exhibited by anti-CD36 antibodies (12P109 and 117 variants) in F293 / hCD36 or F293 / mCD36 cells, as described in Example 3.
[0106] Fig. 7A , Figure 7B , Figure 7C , Fig.7D and Fig. 7E Depicted are graphs of data showing the ability of anti-CD36 antibodies of the present disclosure (12P109, A8A and 117 variants) to inhibit oxLDL uptake in TILs of syngeneic mouse models of colon cancer (CT26, MC38), liver cancer (BNL 1MEA.7R.1), lung cancer (LL2), and melanoma (B16F10), as described in Example 4.
[0107] Fig. 8A , Figure 8B , Figure 8C , Fig.8D , Fig. 8E and Figure 8F Depicted are anti-CD36 antibodies (12P109 and 117 variants) of the present disclosure that inhibit M2 macrophage polarization ( Fig. 8A and Figure 8B ) and oxLDL-induced M2 macrophage activation ( Figure 8C , Fig.8D , Fig. 8E and Figure 8F )'s ability data, as described in Example 5.
[0108] Fig. 9 Describes the expression of MYC after treatment with the anti-CD36 antibody 117_30DA as described in Example 6. OE / p53 KO Tumor growth curve results measured by bioluminescence in HCC model mice.
[0109] Fig. 10A , Fig. 10B and Fig. 10C Depicts the expression of β-catenin after treatment with the anti-CD36 antibody 117_DA57E as described in Example 6. OE / MYC OE Results measured in HCC model mice. Fig. 10A Results of tumor growth curves measured by bioluminescence are shown. Fig. 10B A graph showing endpoint liver weight results. Fig. 10C A graph showing the results of plasma ALT (alanine transaminase) activity analysis. DETAILED DESCRIPTION
[0110] The present disclosure provides antibodies, including humanized antibodies, that specifically bind to CD36 with high affinity, thereby inhibiting, reducing and / or completely blocking the function of CD36 as a cell surface protein involved in immune regulation, particularly the function of CD36-mediated fatty acid and / or oxidized lipid transport (e.g., oxLDL uptake) among the various roles of CD36, such as those detailed in the Background Technology section, including but not limited to the role of CD36 in regulating the function and maintenance or survival (or death, as the case may be) of tumor cells, tumor-associated macrophages (TAMs), MDSCs, regulatory T cells and CD8 T cells.
[0111] Therefore, it is contemplated that any composition or formulation comprising the anti-CD36 antibody of the present invention can be used as a therapeutic agent for treating a disease (e.g., cancer) mediated by the function of CD36 in fatty acid transport. In addition, it is contemplated that the anti-CD36 antibody of the present invention can be used as a therapeutic agent in combination with other therapeutic agents, such as cell therapy, cytokines, and other biological agents or drugs that change the tumor microenvironment and / or increase the immune response, antibody-drug conjugates, antibodies that regulate immune cells, and / or antibodies targeting immune checkpoint molecules, including but not limited to PD1, PD-L1, LAG3, CTLA-4, A2AR, TIM-3, BTLA, CD276, CD328, VTCN1, IDO, KIR, NOX2, VISTA, OX40, CD27, CD28, CD40, CD122, CD137, GITR, ICOS.
[0112] Overview of terms and techniques
[0113] For the description herein and the appended claims, the singular forms "a" and "an" include plural referents unless the context clearly indicates otherwise. Thus, for example, reference to "a protein" includes more than one protein, and reference to "a compound" refers to more than one compound. It is further noted that the claims can be drafted to exclude any optional elements. Therefore, this statement is intended to serve as a prior basis for using such exclusive terms as "only", "only", etc. or using "negative" limitations when recording claim elements. The use of "including" and "comprising" is interchangeable and is not intended to be limiting. It should also be understood that when the description of various embodiments uses the term "comprising", those skilled in the art should understand that in certain specific cases, the embodiments may also be described alternatively using the language of "essentially consisting of..." or "consisting of..."
[0114] When providing a numerical range, unless the context clearly stipulates otherwise, it should be understood that each intermediate integer of the numerical value between the upper and lower limits of the range, and one-tenth of each intermediate integer, unless the context clearly stipulates otherwise, and any other stated or intermediate values within the stated range, are all included in the present invention. The upper and lower limits of these smaller ranges can be independently included in the smaller range, and are also included in the present invention, except for any specific exclusion of the restriction within the scope. When the range includes one or both of the restrictions, the range excluding (i) one of them or (ii) two of those included restrictions is also included in the present invention. For example, "1 to 50" includes "2 to 25", "5 to 20", "25 to 50", "1 to 10" and the like.
[0115] Generally, the nomenclature used herein and the techniques and procedures described herein include those well understood and commonly employed by those of ordinary skill in the art, such as the following common techniques and methodology: Sambrook et al., Molecular Gram Long - Laboratory Manual (2nd ed.), Volumes 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989 (hereinafter referred to as “Sambrook”); Current protocols for molecular biology , F.M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (2011 Supplement) (hereinafter referred to as "Ausubel"); Antibody Engineering , Volumes 1 and 2, edited by R. Kontermann and S. Dubel, Springer-Verlag, Berlin and Heidelberg (2010); Monoclonal Antibodies: Methods and Protocols, V. Ossipow and N. Fischer, eds., 2nd ed., Humana Press (2014); Therapeutic antibodies: from bench to bedside , Z. An, ed., John Wiley & Sons, Hoboken, NJ (2009); and Phage display , Tim Clackson and Henry B. Lowman, eds., Oxford University Press, UK (2004).
[0116] All publications, patents, patent applications, and other documents cited in this disclosure are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application, or other document was individually indicated to be incorporated by reference for all purposes.
[0117] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. It should be understood that the terms used herein are only for the purpose of describing specific embodiments and are not intended to be limiting. For the purpose of explaining the present disclosure, the following term descriptions will apply, and where appropriate, terms used in the singular will also include the plural form, and vice versa.
[0118] As used herein, "CD36" refers to CD36 protein, and as used herein, it covers CD36 protein of human, cynomolgus monkey, mouse and any isoforms of these proteins. The amino acid sequences of various exemplary CD36 proteins are known in the art and are provided in Table 1 below and in the attached sequence listing.
[0119] As used herein, "CD36-mediated conditions" or "CD36-mediated diseases" encompass any medical condition associated with the specific binding of a ligand to the cell surface protein CD36. For example, the specific binding of CD36 to lipids and / or fatty acids plays a role in regulating or increasing the immunosuppressive capacity of TAMs and regulatory T cells in the tumor microenvironment. Thus, CD36-mediated diseases may include, but are not limited to, any disease or condition mediated by and / or responsive to an antagonist or inhibitor of CD36, including, but not limited to, cancer.
[0120] As used herein, "antibody" refers to a molecule comprising one or more polypeptide chains that specifically binds to or is immunoreactive with a specific antigen. Exemplary antibodies of the present disclosure include monoclonal antibodies, polyclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, antibody fusions (e.g., fusion proteins), multispecific antibodies (e.g., bispecific antibodies), monovalent antibodies (e.g., one-armed antibodies), multivalent antibodies, antigen-binding fragments (e.g., Fab', F(ab')2, Fab, Fv, rIgG, and scFv fragments), and synthetic antibodies (or antibody mimetics).
[0121] An "anti-CD36 antibody" or "antibody that binds to CD36" refers to an antibody that binds to CD36 with sufficient affinity such that the antibody can be used as a therapeutic and / or diagnostic agent for targeting CD36. In some embodiments, the extent of binding of an anti-CD36-specific antibody to an unrelated, non-CD36 antigen is less than about 20%, about 15%, about 10%, or about 5% of the binding of the antibody to CD36, as measured by, for example, radioimmunoassay (RIA) or surface plasmon resonance (SPR). In some embodiments, the anti-CD36 antibodies of the present disclosure have a binding affinity of <1 μM, <100 nM, <10 nM, <1 nM, <0.1 nM, <0.01 nM, or <1 pM (e.g., 10 -8 M or smaller, for example, from 10 -8 M to 10 -13 M, for example, from 10 -9 M to 10 -13 The dissociation constant (K D The amino acid sequences of exemplary CD36 proteins of the present disclosure are provided in Table 2 below and in the accompanying sequence listing.
[0122] "Full length antibody," "intact antibody" or "whole antibody" are used interchangeably herein and refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
[0123] "Antibody fusion" refers to an antibody covalently conjugated (or fused) to a polypeptide or protein, typically bound to the end of an antibody light chain (LC) or heavy chain (HC) via a linker. Exemplary antibody fusions contemplated by the present disclosure may include an anti-CD36 antibody fused to a protein via a linker, the protein being a T cell activation or immunostimulatory cytokine, such as IL-2, IL-7, IL-10, IL-12, IL-15, IL-21, or IFN-α.
[0124] "Antibody fragment" refers to a portion of a full-length antibody that is capable of binding to the same antigen as the full-length antibody. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; monovalent or one-armed antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.
[0125] The "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these are further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
[0126] "Variable region" or "variable domain" refers to the domain of an antibody heavy chain or light chain that is involved in binding the antibody to an antigen. The variable domains of the heavy and light chains of a native antibody (V H and V L ) generally have a similar structure, each domain comprising four conserved framework regions (FR) and three hypervariable regions (HVR) (see, e.g., Kindt et al., Kuby Immunology, 6th edition, WH Freeman and colleagues, page 91). A single V H or V L The V domain may be sufficient to confer antigen binding specificity. In addition, the V domain from an antibody that binds the antigen may be sufficient to confer antigen binding specificity. H or V L The domain can separate antibodies that bind to a specific antigen to screen for complementary V L or V H Libraries of domains (see, e.g., Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991)).
[0127] As used herein, "hypervariable region" or "HVR" refers to each of the regions of an antibody variable domain that are hypervariable in sequence and / or form structurally defined loops ("hypervariable loops"). Typically, a native antibody comprises four chains with six HVRs; three in the heavy chain variable domain, V H (HVR-H1, HVR-H2, HVR-H3), and three in the light chain variable domain, V L(HVR-L1, HVR-L2, HVR-L3). The HVRs generally comprise amino acid residues from hypervariable loops and / or from "complementarity determining regions" (CDRs). A large number of hypervariable region descriptions are in use and are covered herein. The Kabat complementarity determining regions (CDRs) are based on sequence variability and are the most commonly used (Kabat et al., Protein Sequences with Immunological Significance, 5th Edition, Public Health Service, National Institutes of Health, Bethesda, Maryland (1991)). Chothia refers to the position of the structural loops (Chothia and Lesk, J.Mol.Biol.196:901-917 (1987)). The AbM hypervariable region represents a compromise between the Kabat CDR and Chothia structural loops and is used by the AbM antibody modeling software of Oxford Molecular. The "Contact" hypervariable region is based on the analysis of available complex crystal structures. The residue ranges of the hypervariable regions defined under these systems are shown in the table below.
[0128]
[0129]
[0130] In addition to the above systems, HVRs and CDRs can be identified using the international ImMunoGeneTics information system (called IMGT / V-Quest), which is described in Brochet, X. et al., Nucl. Acids Res. 36, W503-508 (2008). PMID: 18503082; and available online at www.imgt.org / IMGT_vquest / input. IMGT / V-Quest uses the IMGT unique number to analyze the alignment with the closest germline V gene variable region nucleotide sequence to identify HVRs and CDRs.
[0131] As used herein, a hypervariable region (HVR) may include an expanded or alternative hypervariable region as follows: 27-32, 27-36, 24-34, or 24-38 (HVR-L1); 50-52, 54-56, 50-56, or 54-60 (HVR-L2); 89-97 or 93-101 (HVR-L3); 26-33, 26-35, or 31-35 (HVR-H1); 51-58, 50-61, or 50-66 (H2); and 97-110, 97-112, 99-110, or 99-112 (H3) in V H For each of these definitions, the variable domain residues are numbered according to Kabat et al. (supra).
[0132] As used herein, "complementarity determining region" or "CDR" refers to the region within the HVR of the variable domain with the highest sequence variability and / or involved in antigen recognition. Typically, a native antibody comprises four chains with six HVRs; three in the heavy chain variable domain, V H (CDR-H1, CDR-H2, CDR-H3), and three in the light chain variable domain, V L (CDR-L1, CDR-L2, CDR-L3). Exemplary CDRs occur at variable domain amino acid residue positions: 24-34, 27-32, 27-36, 24-38 (CDR-L1); 50-56, 50-52, 54-56 or 54-60 (CDR-L2); 89-97 or 93-101 (CDR-L3); 31-35 or 26-33 (CDR-H1), 50-66 or 51-58 (CDR-H2); and 99-112, 99-110, 97-112 or 97-110 (CDR-H3).
[0133] "Framework" or "FR" refers to the variable domain residues other than the HVR residues. The FR of the variable domain is usually composed of four domains: FR1, FR2, FR3 and FR4. Therefore, HVR and FR sequences usually appear in the following order: H (or V L ): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
[0134] Unless otherwise indicated, the positions of residues in HVRs, CDRs, FRs and other residues in the variable domain are numbered herein according to Kabat et al. (supra).
[0135] "Native antibodies" refer to naturally occurring immunoglobulin molecules. For example, natural IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains connected by disulfide bonds. From N-terminus to C-terminus, each heavy chain has a variable region (V H ), also called the variable heavy domain or heavy chain variable domain, followed by three constant domains (CH1, CH2 and CH3). Similarly, from N-terminus to C-terminus, each light chain has a variable region (V L ), also called a variable light domain or light chain variable domain, followed by a constant light (CL) domain. Based on the amino acid sequence of its constant domain, the light chain of an antibody can be assigned to one of two types, kappa (κ) and lambda (λ).
[0136] As used herein, "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody group, that is, the individual antibodies comprising the group are identical and / or bind to the same epitope, except for possible variant antibodies (e.g., variant antibodies contain mutations that occur naturally or during the production of monoclonal antibodies, and are generally present in small amounts). Compared to polyclonal antibody preparations that generally contain different antibodies for different determinants (epitopes), each monoclonal antibody prepared by monoclonal antibodies is directed to a single determinant on the antigen. Therefore, the term "monoclonal" means that the characteristic of the antibody is obtained from a substantially homogeneous antibody group, and should not be interpreted as requiring antibodies to be produced by any particular method. For example, the monoclonal antibody used can be prepared by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods for preparing monoclonal antibodies described herein, and other exemplary methods.
[0137] A "chimeric antibody" refers to an antibody in which a portion of the heavy chain and / or light chain is derived from a particular source or species, while the remainder of the heavy chain and / or light chain is derived from a different source or species.
[0138] "Humanized antibody" refers to a chimeric antibody comprising an amino acid sequence from a non-human CDR and an amino acid sequence from a human FR. In certain embodiments, a humanized antibody will comprise substantially all of at least one (and typically two) variable domains, wherein all or substantially all of the CDRs correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, such as a non-human antibody, refers to an antibody that has undergone humanization.
[0139] A "human antibody" refers to an antibody that possesses an amino acid sequence corresponding to that of an antibody produced by a human or human cell, or an antibody derived from a non-human source utilizing a human antibody library or other human antibody encoding sequences. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues.
[0140] The "Human Consensus Framework" is a representation of the human immunoglobulin V L or V H The framework sequence is a selection of the most frequently occurring amino acid residues. L or V HThe sequence is selected from a subset of variable domain sequences. Typically, the subset of sequences is the subset in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols. 1-3. In one embodiment, for V L , said subgroup being subgroup kappa I as in Kabat et al. (supra). In one embodiment, for V H , the subgroup being subgroup III as in Kabat et al. (supra).
[0141] As used herein, an "acceptor human framework" is a light chain variable domain (V L ) framework or heavy chain variable domain (V H ) framework. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence therefrom, or it may comprise amino acid sequence changes. In some embodiments, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, V L The acceptor human framework is identical in sequence to V L The human immunoglobulin framework sequence or human consensus framework sequence is identical.
[0142] "Fc region" refers to a dimer complex comprising the C-terminal polypeptide sequence of an immunoglobulin heavy chain, wherein the C-terminal polypeptide sequence is a sequence that can be obtained by digesting an intact antibody with papain. The Fc region may comprise a native or variant Fc sequence. Although the boundaries of the Fc sequence of an immunoglobulin heavy chain may vary, the human IgG heavy chain Fc sequence is generally defined as extending from an amino acid residue at about Cys226 or at about Pro230 to the carboxyl end of the Fc sequence. However, the C-terminal lysine (Lys447) of the Fc sequence may or may not be present. The Fc sequence of an immunoglobulin generally comprises two constant domains, a CH2 domain and a CH3 domain, and optionally comprises a CH4 domain.
[0143] "Fc receptor" or "FcR" refers to a receptor that binds to the Fc region of an antibody. In some embodiments, FcR is a natural human FcR. In some embodiments, FcR is a receptor (gamma receptor) that binds to an IgG antibody, and includes receptors of FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternative splicing forms of these receptors. FcγRII receptors include FcγRIIA ("activating receptor") and FcγRIIB ("inhibiting receptor"), which have similar amino acid sequences, the difference being mainly in their cytoplasmic domains. Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain (see, e.g., Daeron, Annu. Rev. Immunol. 15: 203-234 (1997)). As used herein, FcR also includes the neonatal receptor FcRn, which is responsible for the transfer of maternal IgG to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)) and the regulation of immunoglobulin homeostasis. FcRs are reviewed in, e.g., Ravetch and Kinet, Annu. Rev. Immunol. 9:457-92 (1991); Capel et al., Immunomethods 4:25-34 (1994); and deHaas et al., J. Lab. Clin. Med. 126:330-41 (1995).
[0144] A "multispecific antibody" is an antibody with at least two different binding sites, each with a different binding specificity. A multispecific antibody can be a full-length antibody or an antibody fragment, and the different binding sites can allow each binding site to bind to a different antigen, or different binding sites can bind to two different epitopes of the same antigen.
[0145] "Fv fragment" refers to an antibody fragment that contains a complete antigen recognition and binding site. This region consists of a dimer of one heavy chain variable domain and one light chain variable domain in tight association, which can be covalent in nature, such as in scFv. In this configuration, the three CDRs of each variable domain interact to form a V H -V L The antigen binding site is defined on the surface of the dimer. In general, six CDRs or a subset thereof confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv containing only three CDRs specific for an antigen) has the ability to recognize and bind to an antigen, although usually with a lower affinity than the entire binding site.
[0146] "Fab fragment" refers to an antibody fragment containing the variable and constant domains of the light chain and the variable domain and the first constant domain (CH1) of the heavy chain. "F(ab')2 fragment" comprises a pair of Fab fragments, which are usually covalently linked by hinge cysteines between them near their carboxyl termini. Other chemical couplings of antibody fragments are also known in the art.
[0147] As used herein, "antigen binding arm" refers to an antibody component that has the ability to specifically bind to a target molecule. Typically, the antigen binding arm is a complex of immunoglobulin polypeptide sequences, such as CDRs and / or variable domain sequences of immunoglobulin light and heavy chains.
[0148] "Single-chain Fv" or "scFv" refers to a V fragment comprising an antibody H and V L Fv polypeptides also contain V H and V L A polypeptide linker between the domains that enables the scFv to form the desired antigen-binding structure.
[0149] "Affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). "Binding affinity" refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can often be measured by the equilibrium dissociation constant (K D ). Affinity can be measured by common methods known in the art (including the methods described herein). Specific illustrative and exemplary embodiments for measuring binding affinity are described below.
[0150] "Specific binding" or "specific binding" means that the antibody binds to the antigen with a specificity of no more than about 1×10 -7 In some embodiments, an antibody may have a secondary affinity for an antigen other than the antigen to which it specifically binds, wherein "secondary affinity" generally refers to the antibody binding to the secondary antigen with an affinity value greater than about 10 nM, as described elsewhere herein. When an antibody may have a secondary affinity for a secondary antigen, such antibody will still specifically bind to the primary antigen.
[0151] An "isolated antibody" refers to an antibody that has been separated from a component of its natural environment. In some embodiments, the antibody is purified to a purity greater than 95% or 99%, as determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase HPLC). For a review of methods for assessing antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87.
[0152] "Effector function" refers to the biological activity attributed to the Fc region of an antibody, which varies with the antibody isotype. Examples of antibody effector functions include: Clq binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptors); and B cell activation.
[0153] "Immunoconjugate" refers to an antibody conjugated to one or more heterologous molecules, including but not limited to a cytotoxic agent.
[0154] "Treatment," "treat," or "treating" refers to clinical intervention that attempts to alter the natural course of a condition in the individual being treated, and may be used for prevention or performed during the course of clinical pathology. Desired outcomes of treatment may include, but are not limited to, preventing the onset or recurrence of a condition, alleviating symptoms, alleviating any direct or indirect pathological consequences of a condition, preventing metastasis, reducing the rate of progression, ameliorating or palliating the disease state, and alleviating or improving prognosis. For example, treatment may include administering to a subject a therapeutically effective amount of a pharmaceutical formulation comprising an anti-CD36 antibody to delay the development or slow the progression of a disease or condition mediated by CD36 and / or its binding to a ligand, or in which CD36 may play a role in the pathogenesis and / or progression.
[0155] "Pharmaceutical preparation" refers to a preparation in a form that allows the biological activity of the active ingredient to be effective, and it does not contain additional components that are toxic to the subject to whom the preparation is administered. A pharmaceutical preparation may include one or more active agents. For example, a pharmaceutical preparation may include an anti-CD36 antibody as the only active agent of the preparation, or may include an anti-CD36 antibody and one or more additional active agents, such as inhibitors of immune checkpoint molecules.
[0156] As used herein, "sole active agent" refers to an active agent in a pharmaceutical formulation that is the only active agent present in the formulation that provides or would be expected to provide a relevant pharmacological effect to treat the condition to be treated in the subject. A pharmaceutical formulation comprising a sole active agent does not exclude the presence of one or more inactive agents, such as a pharmaceutically acceptable carrier, in the formulation. An "inactive agent" is an agent that is not expected to provide or otherwise significantly contribute to a relevant pharmacological effect for the condition that is expected to treat the subject.
[0157] "Pharmaceutically acceptable carrier" refers to ingredients in a pharmaceutical preparation other than the active ingredient, which are non-toxic to the subject to which it is administered. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers or preservatives.
[0158] As used herein, "immune checkpoint molecules" refer to molecules that regulate immune system pathways and thus prevent them from attacking cells unnecessarily. Many immune checkpoint molecules (including both inhibitory and costimulatory) are targets for immunotherapy in the treatment of cancer and viral infections (e.g., using blocking antibodies to block immunosuppression or using agonists to promote immunostimulation). Exemplary immune checkpoint molecules for cancer immunotherapy include but are not limited to PD1, PD-L1, LAG3, CTLA-4, A2AR, TIM-3, BTLA, CD276, CD328, VTCN1, IDO, KIR, NOX2, VISTA, OX40, CD27, CD28, CD40, CD122, CD137, GITR, ICOS.
[0159] A "therapeutically effective amount" refers to the amount of an active ingredient or agent (e.g., a pharmaceutical formulation) that achieves a desired therapeutic or preventive result, such as treating or preventing a disease, disorder, or condition in a subject. In the case of a CD36-mediated disease or condition, a therapeutically effective amount of a therapeutic agent is an amount that reduces, prevents, inhibits, and / or alleviates to some extent one or more of the symptoms associated with the disease, disorder, or condition. For cancer therapy, in vivo efficacy can be measured, for example, by assessing the growth of primary tumors, the occurrence and / or growth of secondary tumors, the occurrence and / or number of metastases, the duration, severity, and / or recurrence of symptoms, response rate (RR), duration of response, and / or quality of life.
[0160] As used herein, "simultaneously" refers to the administration of two or more therapeutic agents, wherein at least a portion of the administration overlaps in time. Thus, simultaneous administration includes a dosing regimen when the administration of one or more agents continues after the administration of one or more other agents has been discontinued.
[0161] "Individual" or "subject" refers to mammals, including, but not limited to, domestic animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats).
[0162] Detailed Description of Various Embodiments
[0163] I.CD36
[0164] CD36 is a multifunctional transmembrane glycoprotein that serves as a cell surface receptor for a wide range of ligands. Typically, CD36 has two different binding domains for the binding of thrombospondin to other lipid ligands, such as oxidized low-density lipoprotein (oxLDL), anionic phospholipids, long-chain fatty acids, and bacterial diacylated lipopeptides. It is believed that the cellular responses mediated by the binding of CD36 to these ligands include fatty acid metabolism, dietary fat processing, angiogenesis, and inflammatory responses. CD36 acts as a co-receptor for TLR4:TLR6 heterodimers, thereby promoting inflammation in monocytes / macrophages. It is believed that upon binding of a ligand, such as oxidized LDL ("oxLDL"), CD36 interacts with the TLR4:TLR6 heterodimer and the complex is internalized, initiating an inflammatory response leading to NF-kappa-B-dependent production of CXCL1, CXCL2, and CCL9 cytokines via the MyD88 signaling pathway, and production of the CCL5 cytokine via the TICAM1 signaling pathway, as well as secretion of IL1B through priming and activation of the NLRP3 inflammasome. Other coreceptors that interact with CD36 have also been described.
[0165] The sequence and annotation of human CD36 (also referred to herein as "hCD36") can be found at UniProt entry P16671, and the full-length 472 amino acid sequence of isoform 1 is shown herein as SEQ ID NO: 58. The sequence and annotation of mouse CD36 (also referred to herein as "mCD36") can be found at UniProt entry Q08857, and the full-length 472 amino acid sequence is shown herein as SEQ ID NO: 60. Table 1 below provides an overview of the sequences of human and mouse CD36 polypeptides used in the present disclosure and their sequence identifiers. These sequences are also included in the accompanying sequence listing.
[0166] Table 1: Human and mouse CD36 polypeptides
[0167]
[0168]
[0169]
[0170] II. Anti-CD36 Antibodies
[0171] In some embodiments, the present disclosure provides anti-CD36 antibodies in various well-known immunoglobulin features (e.g., CDRs, FRs, V H 、V L The structures of the present invention in terms of amino acid and encoding nucleotide sequences of the anti-CD36 antibodies of the present invention (such as the heavy chain, light chain, and full-length heavy chain and light chain) are shown in Table 2 below. Table 2 below provides an overview of the anti-CD36 antibodies of the present invention that were generated and functionally characterized as described in the Examples. The relevant sequences and sequence identifiers of each antibody are provided in Table 2 and are also included in the accompanying sequence listing.
[0172] Table 2: Anti-CD36 antibody sequences
[0173]
[0174]
[0175]
[0176]
[0177]
[0178]
[0179]
[0180]
[0181]
[0182]
[0183]
[0184]
[0185] 1. Anti-CD36 antibody binding affinity and functional properties
[0186] In some embodiments, the equilibrium dissociation constant (K) of an anti-CD36 antibody provided herein for binding to CD36 is D ) is <100 nM, <10 nM, <1 nM, <0.1 nM, <0.01 nM, or <0.001 nM (e.g., 10 -8 M or lower, from 10 -8 M to 10 -13 M, for example, from 10 -9 M to 10-13 M).
[0187] It is contemplated that the various anti-CD36 antibodies generated as disclosed herein include antibodies capable of binding with high affinity to hCD36, mCD36, rhesus CD36, both hCD36 and mCD36, and / or hCD36, mCD36, and rhesus CD36. More specifically, in some embodiments, the anti-CD36 antibodies of the present disclosure are expressed at 1×10 -8 M or less, 1×10 -9 M or less, 1×10 -10 M or less, or 1×10 -11 In some embodiments, the binding affinity is expressed as the equilibrium dissociation constant (K) for binding to the hCD36 polypeptide of SEQ ID NO: 58 or SEQ ID NO: 59. D ). In some embodiments, the anti-CD36 antibodies of the present disclosure are measured at 1×10 -8 M or less, 1×10 -9 M or less, 1×10 -10 M or less, or 1×10 -11 In some embodiments, the binding affinity is expressed as the equilibrium dissociation constant (K) for binding to the mCD36 polypeptide of SEQ ID NO: 60 or SEQ ID NO: 61. D ). In some embodiments, the anti-CD36 antibodies of the present disclosure are measured at 1×10 -8 M or less, 1×10 -9 M or less, 1×10 -10 M or less, or 1×10 -11 In some embodiments, the binding affinity is measured as the equilibrium dissociation constant (K) for binding to the rhesus monkey CD36 polypeptide of SEQ ID NO: 62 or SEQ ID NO: 63. D ). In some embodiments, the anti-CD36 antibodies of the present disclosure are measured at 1×10 -8 M or less, 1×10 -9 M or less, 1×10 -10 M or less, or 1×10 -11 M or less binding affinity to both hCD36 and mCD36. In some embodiments, the anti-CD36 antibodies of the present disclosure bind to both hCD36 and mCD36 with a binding affinity of 1×10 -8 M or less, 1×10 -9 M or less, 1×10 -10 M or less, or 1×10 -11The binding affinity of 5M or lower was found to bind to both hCD36 and rhesus CD36.
[0188] Typically, the binding affinity of a ligand to its receptor can be determined using any of a variety of assays and expressed in the form of a variety of quantitative values. Specific CD36 binding assays that can be used to determine antibody affinity are disclosed in the Examples herein. In addition, antigen binding assays are known in the art and can be used herein, including but not limited to any direct or competitive binding assays using techniques such as Western blots, radioimmunoassays, enzyme-linked immunosorbent assays (ELISAs), "sandwich" immunoassays, surface plasmon resonance-based assays (e.g., BIAcore assays as described in WO2005 / 012359), immunoprecipitation assays, fluorescent immunoassays, protein A immunoassays, flow cytometry, and fluorescence activated cell sorting (FACS) assays, etc.
[0189] Thus, in some embodiments, binding affinity is measured as K D The values are expressed as and reflect intrinsic binding affinity (e.g., with minimized avidity effects). The anti-CD36 antibodies of the present disclosure exhibit strong binding affinity to the hCD36 polypeptide of SEQ ID NO: 58, e.g., exhibiting a K between 10 nM and 1 pM. D Thus, the anti-CD36 antibodies of the present disclosure can compete with antibodies having lower affinity for the same or overlapping epitopes of CD36.
[0190] In some embodiments, the anti-CD36 antibodies provided herein reduce, inhibit and / or completely block the binding of ligands to CD36, and immunomodulation and / or immune signaling mediated by the binding of ligands to CD36, including the maintenance of TAMs in the tumor microenvironment. The ability of antibodies to inhibit these immunomodulatory and immune signaling pathways mediated by the binding of ligands to CD36 can be determined in vitro using known cell-based assays (including the assays described in the Examples of the present disclosure).
[0191] Thus, in some embodiments, the CD36 antibodies of the present disclosure are characterized by one or more of the following functional properties based on the ability to reduce, inhibit and / or completely block intracellular signaling via pathways mediated by CD36.
[0192] In at least one embodiment, the anti-CD36 antibody is present at 1×10 -8 M or less, 1×10 -9 M or less, 1×10 - 10M or less binding affinity to human CD36; optionally, wherein the binding affinity is measured by the equilibrium dissociation constant (K) with the hCD36 polypeptide of SEQ ID NO: 58 or 59 D ) to measure.
[0193] In at least one embodiment of the anti-CD36 antibody, the antibody is expressed in 1×10 -8 M or less, 1×10 -9 M or less, 1×10 -10 M or less binding affinity to mouse CD36; optionally, wherein the binding affinity is measured by the equilibrium dissociation constant (K) with the mCD36 polypeptide of SEQ ID NO: 60 or 61 D ) to measure.
[0194] In at least one embodiment of the anti-CD36 antibody, the antibody is expressed in 1×10 -8 M or less, 1×10 -9 M or less, 1×10 -10 M or less binding affinity to rhesus monkey CD36; optionally, wherein the binding affinity is measured by the equilibrium dissociation constant (K) with the rhesus monkey CD36 polypeptide of SEQ ID NO: 62 or 63 D ) to measure.
[0195] In at least one embodiment of the anti-CD36 antibody, the antibody inhibits CD36-dependent oxidized LDL uptake in F293 cells overexpressing surface human CD36 by at least 65%, at least 75%, at least 85%, at least 95%, or at least 100%; wherein at a concentration of oxLDL of 1-10 μg / mL, the antibody has an IC of 5 nM or less, 1 nM or less, 0.5 nM or less, or 0.1 nM or less. 50 .
[0196] In at least one embodiment of the anti-CD36 antibody, the antibody inhibits CD36-dependent oxidized LDL uptake in U937 cells by at least 65%, at least 75%, at least 85%, at least 95%, or at least 100%; wherein at a concentration of oxLDL of 1-10 μg / mL, the antibody has an IC of 5 nM or less, 1 nM or less, 0.5 nM or less, or 0.1 nM or less. 50 .
[0197] In at least one embodiment of the anti-CD36 antibody, the antibody inhibits CD36-dependent oxidized LDL uptake in mouse CD45+ TILs by at least 65%, at least 75%, at least 85%, at least 95%, or at least 100%; optionally, wherein at a concentration of oxLDL of 1-10 μg / mL, the antibody has an IC of 5 nM or less, 1 nM or less, 0.5 nM or less, or 0.1 nM or less. 50 .
[0198] 2. Anti-CD36 antibody fragment
[0199] In some embodiments, the anti-CD36 antibodies of the present disclosure may be antibody fragments. Antibody fragments that can be used with the binding determinants of the present disclosure include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, scFv fragments, monovalent, single domain antibodies, one-armed or one-armed antibodies, and other fragments described herein and known in the art. Therefore, in some embodiments of the anti-CD36 antibodies of the present disclosure, the antibody is an antibody fragment selected from the group consisting of F(ab')2, Fab', Fab, Fv, single domain antibodies (VHH), one-armed antibodies, and scFv.
[0200] For a review of various antibody fragments, see, for example, Hudson et al. Nat. Med. 9: 129-134 (2003). For a review of scFv fragments, see, for example, Pluckthun's Monoclonal Antibody Pharmacology, Vol. 113, Rosenburg and Moore, ed., (Springer, New York), pp. 269-315 (1994); see also WO93 / 16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For a description of Fab and F(ab')2 fragments comprising salvage receptor binding epitope residues and increased in vivo half-life, see U.S. Pat. No. 5,869,046. Other monovalent antibody formats are described in, for example, WO2007 / 048037, WO2008 / 145137, WO2008 / 145138, and WO2007 / 059782. Monovalent one-armed antibodies are described in, for example, WO2005 / 063816. Diabodies are antibody fragments with two antigen-binding sites that can be bivalent or bispecific (see, for example, EP0404097; WO93 / 01161; Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993)).
[0201] In some embodiments, the antibody fragment is a single domain antibody, which comprises all or part of the heavy chain variable domain or all or part of the light chain variable domain of an antibody. In some embodiments, the single domain antibody is a human single domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Pat. No. 6,248,516).
[0202] Antibody fragments can be made by a variety of techniques including, but not limited to, proteolytic digestion of intact antibodies and production by recombinant host cells (eg, E. coli or bacteriophage), as described herein.
[0203] 3. Chimeric, humanized and human anti-CD36 antibodies
[0204] In some embodiments, the anti-CD36 antibodies of the present disclosure may be chimeric antibodies. (See, e.g., chimeric antibodies described in U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984)). In one embodiment, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate (e.g., monkey)) and a human constant region. In some embodiments, a chimeric antibody is a "class-switched" antibody in which the class or subclass has been changed from that of the parent antibody. It is contemplated that a chimeric antibody may include an antigen-binding fragment thereof.
[0205] In some embodiments, the anti-CD36 antibodies of the present disclosure are humanized antibodies. Typically, non-human antibodies are humanized to reduce immunogenicity to humans while retaining the specificity and affinity of the parent non-human antibodies. Typically, humanized antibodies include one or more variable domains, wherein HVR, CDR (or portions thereof) are derived from non-human antibodies, and FR (or portions thereof) are derived from human antibody sequences. Humanized antibodies may also optionally include at least a portion of human constant regions. In some embodiments, some FR residues in humanized antibodies are replaced by corresponding residues from non-human antibodies (e.g., antibodies from which CDR residues are derived) to restore or improve antibody specificity or affinity.
[0206] Humanized antibodies and methods for making them are reviewed, e.g., in Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and further described, e.g., in Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Natl. Acad. Sci. USA 86:10029-10033 (1989); U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (describing SDR(a-HVR) grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (describing "surface remodeling"); Dall'Acqua et al., Methods 36:25-34 (2005) (describing SDR(a-HVR) grafting); 36:43-60 (2005) (describing "FR shuffling"); and Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer, 83:252-260 (2000) (describing the "guided selection" approach to FR shuffling).
[0207] Human framework regions that can be used for humanization include, but are not limited to, framework regions selected using the "best fit" method (see, e.g., Sims et al., J. Immunol. 151:2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter et al., Proc. Natl. Acad. Sci. USA 89:4285 (1992); and Presta et al., J. Immunol. 151:2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008)); and framework regions derived from screening FR libraries (see, e.g., Baca et al., J. Biol. Chem. 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271:22611-22618 (1996)).
[0208] In some embodiments, the anti-CD36 antibodies of the present disclosure may be human antibodies. Human antibodies can be produced using various techniques known in the art. Human antibodies are generally described in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20: 450-459 (2008). Human antibodies can be prepared by administering immunogens to transgenic animals that have been modified to produce complete human antibodies or complete antibodies with human variable regions in response to antigenic attack. Such animals typically contain all or part of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or are present outside the chromosomes or randomly integrated into the chromosomes of the animal. In such transgenic mice, the endogenous immunoglobulin loci are generally inactivated. For a review of methods for obtaining human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23: 1117-1125 (2005). See also, e.g., U.S. Patent Nos. 6,075,181 and 6,150,584 for XENOMOUSE TM Technology; U.S. Patent No. 5,770,429 Technology; KM in U.S. Patent No. 7,041,870 Technology; and U.S. Patent Application Publication No. US2007 / 0061900 Human variable regions from intact antibodies produced by such animals can be further modified, for example by combining with different human constant regions.
[0209] Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for producing human monoclonal antibodies have been described. See, for example, Kozbor J. Immunol, 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Technology and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol. 147: 86 (1991). Human antibodies produced via human B cell hybridoma technology are also described in Li et al., Proc. Natl. Acad. Sci. USA 103: 3557-3562 (2006). Additional methods include, for example, the method described in U.S. Pat. No. 7,189,826 (describing the production of monoclonal human IgM antibodies from hybridoma cell lines). Human hybridoma technology is also described in Vollmers and Brandlein, Histology and Histopathology, 20(3):927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology 27(3):185-91 (2005).
[0210] Human antibodies can also be produced by isolating Fv clone variable domain sequences selected from human phage display libraries. Such variable domain sequences can then be combined with desired human constant domains. The following describes techniques for selecting human antibodies from antibody libraries.
[0211] 4. Library-derived variants of anti-CD36 antibodies
[0212] In at least one embodiment, improved variants of anti-CD36 antibodies can be isolated by screening combinatorial libraries to find antibodies with desired improved functional properties (e.g., binding affinity or cross-reactivity). For example, various methods are known in the art for generating phage display libraries and screening such libraries to find variant antibodies with improved binding properties. Other methods for generating such library-derived antibodies can be found in, e.g., Hoogenboom et al., Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001); McCafferty et al., Nature 348:552-554 (1990); Clackson et al., Nature 352:624-628 (1991); Marks et al., J. Mol. Biol. 222:581-597 (1992); Marks and Bradbury, M. Methods in Molecular Biology 248:161-175 (Lo, ed., Human Press, Totowa, NJ, 2003); Sidhu et al., J. Mol. Biol. 338(2):299-310 (2004); Lee et al., J. Mol. Biol. 340(5):1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34):12467-12472 (2004); and Lee et al., J. Immunol. Methods 284(1-2):119-132 (2004).
[0213] 5. Multispecific antibodies and antibody fusions
[0214] In at least one embodiment, it is contemplated that the anti-CD36 antibodies of the present disclosure may be multispecific antibodies, such as bispecific antibodies. In some embodiments, the multispecific antibody has at least two different binding sites, each binding site having binding specificity for different antigens, at least one of which specifically binds to CD36. In at least one embodiment, it is contemplated that the multispecific antibody is a bispecific antibody comprising specificity for CD36 and specificity for another antigen that mediates immune regulation, immune signaling, and / or is expressed on cancer or tumor cells. For example, another specificity may be for immune checkpoint molecules, such as PD1, LAG3, CTLA-4, A2AR, TIM-3, BTLA, CD276, CD328, VTCN1, IDO, KIR, NOX2, VISTA, OX40, CD27, CD28, CD40, CD122, CD137, GITR, or ICOS.
[0215] Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs with different specificities (see, e.g., Milstein and Cuello, Nature, 305:537 (1983), WO93 / 08829, and Traunecker et al., EMBO J. 10:3655 (1991)). "Knobs-in-holes" engineering can also be used to generate bispecific antibodies for use with the anti-CD36 antibodies of the present disclosure. Techniques for knobs-in-holes engineering are known in the art and are described, e.g., in U.S. Pat. No. 5,731,168.
[0216] Multispecific antibodies can also be made by engineering an "electrostatic steering" effect that favors the formation of Fc-heterodimer antibody molecules rather than homodimers (WO2009 / 089004A1); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980 and Brennan et al., Science 229:81 (1985)); using leucine zippers to produce bispecific antibodies (see, e.g., Kostelny et al., J. Immunol. 148(5):1547-1553 (1992)); using "diabody" technology to make bispecific antibody fragments (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993)); using single-chain Fv (scFv) dimers (see, e.g., Gruber et al., J. Immunol. 152:5368 (1994)); or trispecific antibodies (see, e.g., Tutt et al., J. Immunol. 147:60 (1991)).
[0217] In at least one embodiment, the anti-CD36 antibodies provided herein may include antibody fusions with proteins. Methods for preparing and using antibody fusions or fusion proteins are well known in the art. Typically, antibodies are covalently conjugated (or fused) to proteins, typically via a linker polypeptide. The conjugation may occur via the end of the light chain (LC) or heavy chain (HC) of the antibody. Antibody fusions may also be prepared using antibody fragments. In an exemplary embodiment of an antibody fusion contemplated by the present disclosure, the fusion includes a full-length anti-CD36 antibody, which is fused to a T cell activation or immunostimulatory cytokine via a linker located at the end of the light chain or heavy chain. The cytokine may include, but is not limited to, IL-2, IL-7, IL-10, IL-12, IL-15, IL-21, or IFN-α. Such anti-CD36 antibody fusions may block activity mediated by CD36 signaling and provide an immunostimulatory cytokine effect. The ability of such anti-CD36 antibody fusions to provide an immunostimulatory cytokine effect may be determined in vitro using a known cell-based assay associated with the cytokine.
[0218] 6. Variants of anti-CD36 antibodies
[0219] In some embodiments, variants of the anti-CD36 antibodies of the present disclosure are considered to have improved properties, such as the binding affinity and / or other biological properties of the antibody. Variants can be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody or by peptide synthesis. Such modifications include, for example, deletions within the amino acid sequence of the antibody and / or insertions into the amino acid sequence of the antibody and / or substitutions of residues within the amino acid sequence of the antibody. Any combination of deletions, insertions and substitutions can be performed to obtain the final construct, provided that the final construct possesses the desired CD36 antigen binding properties.
[0220] A. Substitution, Insertion, and Deletion Variants
[0221] In some embodiments, anti-CD36 antibody variants having one or more amino acid substitutions other than those described herein are provided. Sites for mutagenesis may include CDRs, HVRs, and FRs. Typical "conservative" amino acid substitutions and / or substitutions based on general side chain categories or properties are well known in the art and may be used in embodiments of the present disclosure. The present disclosure also contemplates variants based on non-conservative amino acid substitutions, in which members of one of the amino acid side chain categories are exchanged for amino acids from another category. Amino acid side chains are generally grouped according to the following categories or general properties: (1) hydrophobic: Met, Ala, Val, Leu, Ile, norleucine; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) affecting chain direction: Gly, Pro; and (6) aromatic: Trp, Tyr, Phe. Techniques for substituting amino acids into antibodies and subsequently screening for the desired function (eg, retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC) are well known in the art.
[0222] Amino acid substitution variants may also include variants with one or more substitutions in the hypervariable region of the parent antibody. Typically, the resulting variants selected for further study will have modifications (e.g., increased affinity, reduced immunogenicity) relative to certain biological properties of the parent antibody and / or will retain certain biological properties of the parent antibody. Exemplary substitution variants are affinity-matured antibodies that can be conveniently produced using affinity maturation techniques based on phage display. In short, one or more HVR residues are mutated, and the variant antibodies are displayed on phage and screened for specific biological activity (e.g., binding affinity).
[0223] A useful method for identifying antibody residues or regions that may be targeted for mutagenesis is "alanine scanning mutagenesis" (see, e.g., Cunningham and Wells, Science 244: 1081-1085 (1989)). In this method, a residue or a group of target residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) is identified and replaced by neutral or negatively charged amino acids (e.g., Ala or polyalanine) to determine whether the interaction of the antibody with the antigen is affected. Further substitutions may be introduced at amino acid positions that have been shown to be functionally sensitive to the initial substitutions. Alternatively, or in addition, a crystal structure of an antigen-antibody complex to identify contact points between the antibody and the antigen may be determined. Such contact residues and adjacent residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the desired properties.
[0224] Amino acid sequence insertions that can be prepared include amino and / or carboxyl terminal fusions ranging in length from one residue to polypeptides containing one hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include antibodies with an N-terminal methionyl residue. Other insertion variants of antibody molecules can include fusions of the N-terminus or C-terminus of an antibody with an enzyme or polypeptide, which can increase the serum half-life of the antibody.
[0225] Other residue substitutions can be made in the HVR to improve antibody affinity. Such changes can be made in "hot spots", i.e., residues encoded by codons that undergo high frequency mutations during the somatic maturation process (see, e.g., Chowdhury, Methods Mol. Biol. 207: 179-196 (2008)), and the resulting variant VH or VL tested for binding affinity. In one embodiment, affinity maturation can be performed by constructing and reselecting from secondary libraries (see, e.g., in Hoogenboom et al., Methods in Molecular Biology 178: 1-37 (O'Brien et al., eds., Human Press, Totowa, NJ, (2001)). Another method for introducing diversity involves an HVR-directed approach, in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding can be specifically identified, e.g., using alanine scanning mutagenesis or modeling. HVR-H3 and HVR-L3 are typically specifically targeted. In general, substitutions, insertions, or deletions can be made within one or more HVRs, as long as such changes do not substantially reduce the ability of the antibody to bind antigen. For example, conservative changes that do not substantially reduce binding affinity can be made in HVRs (e.g., conservative substitutions as provided herein). Such changes may be outside of HVR "hot spots."
[0226] In some embodiments, it is contemplated that the anti-CD36 antibodies described herein may be substituted with cysteine residues at specific non-HVR positions to create reactive thiol groups. Such engineered "sulfo-monoclonal antibodies" can be used to conjugate antibodies to, for example, drug moieties or linker-drug moieties to create immunoconjugates, as described elsewhere herein. Cysteine engineered antibodies can be produced as described, for example, in U.S. Patent No. 7,521,541. In some embodiments, any one or more of the following antibody residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region.
[0227] B. Glycosylation variants
[0228] In some embodiments, the anti-CD36 antibodies of the present disclosure are changed to increase or decrease the degree to which the antibodies are glycosylated. The addition or deletion of the glycosylation sites of the antibodies can be carried out by changing the amino acid sequence, thereby creating or removing one or more glycosylation sites. In embodiments where the antibody comprises an Fc region, the carbohydrate attached to the Fc region can be changed. Typically, the natural antibodies produced by mammalian cells comprise branched biantennary oligosaccharides of asparagine at about position 297 ("N297") attached to the CH2 domain of the Fc region by N connection (see, e.g., Wright et al., TIBTECH 15:26-32 (1997)). Oligosaccharides may include various carbohydrates, such as mannose, N-acetylglucosamine (GlcNAc), galactose and sialic acid, and fucose attached to GlcNAc in the "stem" of the biantennary oligosaccharide structure. In some embodiments, oligosaccharide modifications in the Fc region of the antibody can create variants with certain improved properties.
[0229] In some embodiments, the anti-CD36 antibodies of the present disclosure may be variants comprising carbohydrate structures lacking fucose attached (directly or indirectly) to the Fc region. For example, the amount of fucose in such antibodies may be from about 1% to about 80%, from about 1% to about 65%, from about 5% to about 65%, or from about 20% to about 40%. The amount of fucose may be determined by calculating the average amount of fucose within the sugar chain attached to residue N297 relative to the sum of all sugar structures attached to N297 (e.g., complex, mixed, and high mannose structures), as measured by MALDI-TOF mass spectrometry (see, e.g., WO2008 / 077546).
[0230] In some embodiments, the fucosylation variant can provide improved ADCC function of the variant antibody. See, for example, U.S. Patent Publication Nos. US2003 / 0157108 or US2004 / 0093621. Examples of "defucosylated" or "fucose-deficient" antibodies and related methods for making them are disclosed in, for example, US2003 / 0157108; US2003 / 0115614; US2002 / 0164328; US2004 / 0093621; US2004 / 0132140; US2004 / 0110704; US2004 / 0110282; US2004 / 0109865; WO2000 / 61739; WO2000 1 / 29246; WO2003 / 085119; WO2003 / 084570; WO2005 / 035586; WO2005 / 035778; WO2005 / 053742; WO2002 / 031 140; Okazaki et al., J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al., Biotech. Bioeng. 87:614 (2004). Cell lines for producing defucosylated antibodies include Led 3 CHO cells deficient in protein fucosylation (see, e.g., Ripka et al., Arch. Biochem. Biophys. 249:533-545 (1986); US2003 / 0157108 and WO2004 / 056312) and knockout cell lines, such as α-1,6-fucosyltransferase gene FUT8 knockout CHO cells (see, e.g., Yamane-Ohnuki et al., Biotech. Bioeng. 87:614 (2004); Kanda, Y. et al., Biotechnol. Bioeng. 94(4):680-688 (2006) and WO2003 / 085107).
[0231] C. Fc Region Variants
[0232] In some embodiments, the anti-CD36 antibodies of the present disclosure may comprise one or more amino acid modifications (i.e., Fc region variants) in the Fc region. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region) comprising an amino acid substitution at one or more amino acid residue positions. A wide range of Fc region variants known in the art that can be used for the anti-CD36 antibodies of the present disclosure are described below.
[0233] In some embodiments, the anti-CD36 antibody is an Fc region variant with altered effector function. In some embodiments, the antibody with altered effector function has some (but not all) effector functions, reduced effector functions, or no effector functions (e.g., no effector) of the parent antibody. For certain applications in which effector functions (such as ADCC) are unnecessary or harmful, and / or the in vivo half-life of the antibody is important, effector-free Fc region variants are more desirable. Fc region variant antibodies with reduced effector or no effector function may be caused by amino acid substitutions at one or more of the following Fc region positions: 238, 265, 269, 270, 297, 327, and 329. (See, e.g., U.S. Patent No. 6,737,056). Such Fc region variants may include amino acid substitutions at two or more of positions 265, 269, 270, 297, and 327. Such Fc region variants may also include substitution of both residues 265 and 297 to alanine (see, eg, US Pat. No. 7,332,581).
[0234] Some Fc region variants are capable of providing enhanced or reduced binding to FcRs (see, e.g., U.S. Pat. No. 6,737,056; WO 2004 / 056312; and Shields et al., J. Biol. Chem. 9(2): 6591-6604 (2001)). Some Fc region variants capable of providing improved ADCC comprise one or more amino acid substitutions, e.g., at positions 298, 333, and / or 334 of the Fc region (based on EU numbering). Fc region variants with altered (i.e., enhanced or reduced) Clq binding and / or complement dependent cytotoxicity (CDC) are described, e.g., in U.S. Pat. No. 6,194,551, WO 99 / 51642, and Idusogie et al., J. Immunol. 164: 4178-4184 (2000).
[0235] Some Fc region variants are disclosed in, for example, US2005 / 0014934A1 (Hinton et al.) to provide increased half-life and improved binding to neonatal Fc receptors (FcRn). Such Fc region variants comprise amino acid substitutions at one or more of the following positions: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424, and 434. Other Fc region variants with increased half-life include the YTE mutation group (i.e., M252Y / S254T / T256E) at positions 252, 254, and 256 described in, for example, US7658921B2 (Dall'Acqua et al.). Additional examples of Fc region variants can be found in, e.g., U.S. Patent Nos. 5,648,260 and 5,624,821; and WO 94 / 29351.
[0236] Typically, in vitro and / or in vivo cytotoxicity assays can be performed to confirm the reduction / depletion of CDC and / or ADCC activity in Fc region variants. For example, Fc receptor (FcR) binding assays can be performed to ensure that the antibody lacks FcγR binding (and therefore may lack ADCC activity) but retains FcRn binding ability. NK cells, the main cells used to mediate ADCC, express only FcγRIII, while monocytes express FcγRI, FcγRII and FcγRIII. Non-limiting examples of in vitro assays for evaluating ADCC activity of target molecules are described in U.S. Pat. Nos. 5,500,362 (see, e.g., Hellstrom et al., Proc. Natl. Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom et al., Proc. Natl. Acad. Sci. USA 82:1499-1502 (1985); 5,821,337 (see Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)). Alternatively, non-radioactive assays may be used (see, e.g., ACTI for flow cytometry). TM Nonradioactive cytotoxicity assay (Cell Technology, Inc. Mountain View, CA); and Non-radioactive cytotoxicity assay (Promega, Madison, WI). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively, or in addition, ADCC activity of the target molecule can be assessed in vivo, for example in an animal model (such as that disclosed in Clynes et al., Proc. Natl. Acad. Sci. USA 95:652-656 (1998)). Clq binding assays can also be performed to confirm that the antibody cannot bind Clq and therefore lacks CDC activity. See, for example, Clq and C3c binding ELISAs in WO2006 / 029879 and WO2005 / 100402. To assess complement activation, a CDC assay can be performed (see, e.g., Gazzano-Santoro et al., J. Immunol. Methods 202: 163 (1996); Cragg, MS et al., Blood 101: 1045-1052 (2003); and Cragg, MS and MJ Glennie, Blood 103: 2738-2743 (2004)). FcRn binding and in vivo clearance / half-life assays can be performed using methods known in the art (see, e.g., Petkova et al., Intl. Immunol. 18(12): 1759-1769 (2006)).
[0237] D. Non-protein antibody derivatives - immunoconjugates
[0238] In some embodiments, the anti-CD36 antibodies of the present disclosure can be further modified (i.e., derivatized) with non-protein moieties. Non-protein moieties suitable for antibody derivatization include, but are not limited to, water-soluble polymers, such as polyethylene glycol (PEG), copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acid homopolymers or random copolymers, and dextran or poly (n-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. In some embodiments, methoxypolyethylene glycol propionaldehyde can be used to modify antibodies. The polymer can be of any molecular weight and can be branched or unbranched. The number of polymers attached to the antibody can vary, and if more than one polymer is attached, they can be the same or different molecules. Generally, the amount and / or type of polymer used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody, for example, whether the antibody derivative will be used in therapy under a particular condition.
[0239] In some embodiments, the anti-CD36 antibodies of the present disclosure may also be immunoconjugates, wherein the immunoconjugates comprise anti-CD36 antibodies conjugated to one or more cytotoxic agents. Suitable cytotoxic agents contemplated by the present disclosure include chemotherapeutic agents, drugs, growth inhibitors, toxins (e.g., protein toxoids, enzymatic toxins of bacterial, fungal, plant or animal origin, or fragments thereof) or radioactive isotopes. In some embodiments, the immunoconjugates are antibody-drug conjugates (ADCs), wherein the anti-CD36 antibodies as described herein are conjugated to one or more drugs. In some embodiments, the immunoconjugates of the present disclosure comprise anti-CD36 antibodies as described herein conjugated to drugs or therapeutic agents for treating CD36-mediated diseases or conditions.
[0240] In some embodiments, an anti-CD36 antibody as described herein can be conjugated to an enzymatically active toxin or fragment thereof, including but not limited to diphtheria toxin A chain, a non-binding active fragment of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii protein, Dianthus caryophyllus protein, Phytolaca americana protein, Momordica charantia inhibitor, Curcuma curcas toxin, croton toxin, saponin inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and trichothecenes.
[0241] In some embodiments, the immunoconjugates of the present disclosure comprise an anti-CD36 antibody as described herein conjugated to a radioisotope (i.e., a radioconjugate). A variety of radioisotopes can be used to produce such radioconjugates. Examples include 211 At 131 I. 125 I. 90 Y. 186 Re, 188 Re, 153 Sm, 212 Bi, 32 P. 212 In some embodiments, the immunoconjugate may contain a radioisotope for scintigraphic detection, or a spin label for NMR detection or MRI. Suitable radioisotopes or spin labels may include, for example 123 I. 131 I. 111 In, 13 C. 19 F. 15 N. 17 Various isotopes of O, Gd, Mn and Fe.
[0242] Immunoconjugates of anti-CD36 antibodies and cytotoxic agents can be prepared using a variety of well-known bifunctional agents and chemistries suitable for conjugation to proteins. Such agents include, but are not limited to, N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (e.g., dimethyl adipimide HQ), active esters (e.g., disuccinimidyl suberate), aldehydes (e.g., glutaraldehyde), bis-azido compounds (e.g., bis-(p-azidobenzoyl)-hexanediamine), bis-diazonium derivatives (e.g., bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (e.g., toluene-2,6-diisocyanate), and bis-active fluorine compounds (e.g., 1,5-difluoro-2,4-dinitrobenzene). Reagents used to prepare the immunoconjugates of the present disclosure may also include commercially available "cross-linking" reagents, such as: BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC and sulfo-SMPB and SVSB (succinimidyl-(4-vinyl sulfone) benzoate) (see, e.g., Pierce Biotechnology, Inc., Rockford, IL., USA).
[0243] III. Recombinant Methods and Compositions
[0244] The anti-CD36 antibodies of the present disclosure can be produced using recombinant methods and materials well known in the field of antibody production. In some embodiments, the present disclosure provides isolated polynucleotides encoding the anti-CD36 antibodies of the present disclosure or fragments or domains of anti-CD36 antibodies. For example, the isolated polynucleotides can encode amino acid sequences comprising the CDRs or HVRs disclosed herein, V sequences comprising the antibodies, or domains of the present disclosure. L Domain and / or V H The isolated polynucleotides may encode the amino acid sequence of the CDR-H1, CDR-H2 and CDR-H3 sequences of any anti-CD36 antibody disclosed herein, or the amino acid sequence of the complete light chain and / or heavy chain of the anti-CD36 antibody. In at least one embodiment, the isolated polynucleotides may encode the amino acid sequence of the CDR-H1, CDR-H2 and CDR-H3 sequences of any anti-CD36 antibody disclosed herein, or the amino acid sequence of the CDR-L1, CDR-L2 and CDR-L3 sequences. Similarly, it is contemplated that the isolated polynucleotides may encode the amino acid sequence of the V domain of the anti-CD36 antibody disclosed herein. L Domain or V H The amino acid sequence of a domain or a complete heavy chain (HC) or light chain (LC).
[0245] In some embodiments, the present disclosure also provides vectors (e.g., expression vectors) comprising polynucleotide sequences encoding anti-CD36 antibodies or fragments or domains of anti-CD36 antibodies of the present disclosure (as described above). Such vector constructs comprising polynucleotides for recombinant production of antibodies are well known in the art. In addition, in some embodiments, host cells comprising polynucleotides or vectors having sequences encoding anti-CD36 antibodies or fragments or domains of anti-CD36 antibodies of the present disclosure are provided. In at least one embodiment, the host cell is a cell that has been transformed with a vector comprising a V encoding an antibody. L The amino acid sequence of the V domain and / or the V domain of the anti-CD36 antibody of the present disclosure H In another embodiment, the host cell has been transformed with a first vector and a second vector, wherein the first vector comprises a V encoding an antibody. L The second vector comprises a polynucleotide sequence encoding an amino acid sequence of H A nucleic acid having an amino acid sequence.
[0246] In some embodiments of the recombinant method, the host cell used is a eukaryotic cell, such as a Chinese hamster ovary (CHO) cell or a lymphoid cell (e.g., Y0, NS0, Sp20). In one embodiment, a method for preparing an anti-CD36 antibody is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the antibody (as described above) under conditions suitable for expressing the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).
[0247] In short, the recombinant production of anti-CD36 antibodies is carried out by isolating nucleic acid encoding the antibody (e.g., as described herein) and inserting the nucleic acid into one or more vectors for further cloning and / or expression in a host cell. Such nucleic acids can be easily isolated and sequenced using conventional procedures well known in the art (e.g., by using oligonucleotide probes that can specifically bind to genes encoding the heavy and light chains of the desired antibody). Suitable host cells and culture methods for cloning or expressing vectors encoding the antibody are well known in the art and include prokaryotic cells or eukaryotic cells. Typically, after expression, the antibody can be separated and further purified from the cytoplasm as a soluble fraction. In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been "humanized," resulting in the production of antibodies with partially or fully human glycosylation patterns (see, e.g., Gerngross, Nat. Biotech. 22: 1409-1414 (2004), and Li et al., Nat. Biotech. 24: 210-215 (2006)).
[0248] Suitable host cells for expressing the glycosylated anti-CD36 antibodies of the present disclosure can also be derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Many baculovirus strains have been identified that can be used in conjunction with insect cells, particularly for transfecting Spodoptera frugiperda cells. Plant cell cultures can also be used as hosts (see, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, and 7,125,978).
[0249] Examples of mammalian host cell lines that can be used to produce the anti-CD36 antibodies of the present disclosure include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells (see, e.g., Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); myeloma cell lines such as Y0, NS0 and Sp2 / 0; monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney cell line (293 or 293 cells, as described, for example, in Graham et al., J. Gen. Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse Sertoli cells (TM4 cells, as described, for example, in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TR1 cells (see, e.g., Mather et al., Annals NY Acad. Sci. 383:44-68 (1982) and U.S. Pat. No. 6,235,498); Medical Research Council 5 (MRC 5) cells (e.g., cells available from ATCC and also known as CCL-171); and foreskin 4 (FS-4) cells (see, e.g., Vilcek et al., Ann. NY Acad. Sci. 284:703-710 (1977), Gardner and Vilcek, J. Gen. Virol. 44:161-168 (1979), and Pang et al., Proc. Natl. Acad. Sci. USA 77:5341-5345 (1980)). For a general review of useful mammalian host cell lines for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKC Lo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003).
[0250] IV. Pharmaceutical Compositions and Formulations of Anti-CD36 Antibodies
[0251] The present disclosure also provides pharmaceutical compositions and pharmaceutical preparations comprising anti-CD36 antibodies. In some embodiments, the present disclosure provides pharmaceutical preparations comprising anti-CD36 antibodies as described herein and pharmaceutically acceptable carriers. In some embodiments, anti-CD36 antibodies are the sole active agent of the pharmaceutical composition. Such pharmaceutical preparations can be prepared by mixing anti-CD36 antibodies with the desired purity with one or more pharmaceutically acceptable carriers. Typically, such antibody preparations can be prepared as aqueous solutions (see, e.g., U.S. Patent No. 6,171,586 and WO2006 / 044908) or as lyophilized preparations (see, e.g., U.S. Patent No. 6,267,958).
[0252] Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed. A wide range of such pharmaceutically acceptable carriers are well known in the art (see, e.g., Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)). Exemplary pharmaceutically acceptable carriers that can be used in the formulations of the present disclosure may include, but are not limited to: buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol; butyl alcohol or benzyl alcohol; alkyl parabens such as methyl or propyl parabens; catechol; resorcinol; cyclohexanol; 3-pentanol and m-cresol); low molecular weight (less than about 10 residues) polypeptides; Proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrins; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions, such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants, such as polyethylene glycol (PEG).
[0253] Pharmaceutically acceptable carriers useful in the formulations of the present disclosure may also include interstitial drug dispersants, such as soluble neutral active hyaluronidase glycoprotein (sHASEGP) (see, e.g., U.S. Patent Publication Nos. 2005 / 0260186 and 2006 / 0104968), such as human soluble PH-20 hyaluronidase glycoprotein (e.g., rHuPH20 or Baxter International, Inc.).
[0254] It is also contemplated that the formulations disclosed herein may contain active ingredients in addition to anti-CD36, which are necessary for the specific indication being treated in the subject to which the formulation is administered. Preferably, any additional active ingredient has an activity that is complementary to the activity of the anti-CD36 antibody, and these activities do not adversely affect each other.
[0255] In some embodiments, the pharmaceutical composition comprises an anti-CD36 antibody and an additional active agent for cancer treatment, such as an immune checkpoint inhibitor. Checkpoint inhibitors that can be used for such embodiments include, but are not limited to, a second antibody comprising specificity for an antigen as an immune checkpoint molecule. In some embodiments, the second antibody comprises specificity for immune checkpoint molecules selected from PD1, PD-L1, LAG3, CTLA-4, A2AR, TIM-3, BTLA, CD276, CD328, VTCN1, IDO, KIR, NOX2, VISTA, OX40, CD27, CD28, CD40, CD122, CD137, GITR, and ICOS. In at least one embodiment, the pharmaceutical composition comprises an anti-CD36 antibody and other active agents, wherein the other active agents are antibodies comprising specificity for the immune checkpoint molecule PD1. Exemplary antibodies that can be used for the pharmaceutical composition embodiments disclosed herein that have specificity for PD1 include, but are not limited to, dostatin, pembrolizumab, nivolumab, and pidilizumab.
[0256] It is also contemplated that, in some embodiments, the present disclosure provides a pharmaceutical composition or formulation for use in therapy, wherein the composition further comprises a T cell activation cytokine or an immunostimulatory cytokine. Such cytokines are well known in the field of immunotherapy and include, but are not limited to, IL-2, IL-7, IL-10, IL-12, IL-15, IL-21, and IFN-α. In at least one embodiment, the immunostimulatory cytokine can be provided in the composition as a fusion of an anti-CD36 antibody.
[0257] The active ingredient can be encapsulated in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, in hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in macroemulsions, respectively. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).
[0258] In some embodiments, the formulation may be a sustained-release preparation of the antibody and / or other active ingredients. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, such as films or microcapsules.
[0259] Typically, the formulations of the present disclosure to be administered to a subject are sterile. Sterile formulations can be readily prepared using well-known techniques, such as filtration through sterile filtration membranes.
[0260] V. Uses and methods of treatment
[0261] It is contemplated that any composition or formulation comprising an anti-CD36 antibody of the present disclosure can be used in any method or use, such as in a therapeutic method that utilizes its ability to specifically bind to CD36, thereby inhibiting, reducing and / or completely blocking the function of CD36 as a cell surface protein involved in immunomodulation or signaling, in particular the function of CD36 to regulate the uptake of lipoproteins, fatty acids and other ligands that are involved in the survival and maintenance or survival (or death, as the case may be) of tumor cells, tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), regulatory T cells and CD8 T cells. For example, regulatory T cells are a major cellular component of the tumor microenvironment (TME) and contribute significantly to tumor growth and progression, while CD8 T cells help control tumor growth by killing tumor cells. Inhibition of CD36 binding can deplete regulatory T cells while increasing CD8 T cell survival and function, thereby inducing an increase in anti-tumor T cell responses.
[0262] There are a series of diseases, disorders and conditions that can be potentially treated by inhibiting, reducing and / or completely blocking the immunomodulatory and / or immune signaling activity of CD36 (particularly the effect of CD36 on TAMs). Diseases, disorders and conditions include, but are not limited to, cancer, including, but not limited to, colon cancer, pancreatic cancer, ovarian cancer, HCC, kidney cancer, breast cancer, lung cancer, gastric cancer, melanoma, head and neck cancer, or oral cancer. It is contemplated that any composition or formulation comprising an anti-CD36 antibody of the present disclosure can be used to treat any method or use of the cancer listed above. In some embodiments, the cancer is selected from colon cancer, pancreatic cancer, ovarian cancer, HCC, kidney cancer, breast cancer, lung cancer, gastric cancer, melanoma, head and neck cancer, or oral cancer. In some embodiments, the present disclosure provides a method for treating cancer in a subject, the method comprising administering a therapeutically effective amount of an anti-CD36 antibody of the present disclosure to a subject in need thereof or administering a therapeutically effective amount of a pharmaceutical composition comprising an anti-CD36 antibody of the present disclosure and a pharmaceutically acceptable carrier to the subject.
[0263] As disclosed herein, including in the following examples, the anti-CD36 antibodies of the present disclosure have the ability to reduce, inhibit and / or block the binding of ligands to CD36, thereby altering the immune signaling pathway mediated by CD36. Therefore, in some embodiments, the present disclosure provides a method for treating a CD36-mediated disease or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of an anti-CD36 antibody of the present disclosure or administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an anti-CD36 antibody of the present disclosure and a pharmaceutically acceptable carrier. Similarly, in some embodiments, the present disclosure provides a method for treating a disease mediated by binding to CD36 expressed on a cell in a subject, the method comprising administering to the subject a therapeutically effective amount of an anti-CD36 antibody of the present disclosure or administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an anti-CD36 antibody of the present disclosure and a pharmaceutically acceptable carrier.
[0264] Administration of an anti-CD36 antibody, composition or pharmaceutical formulation according to the treatment method provides an antibody-induced therapeutic effect that protects the subject from progression of a CD36-mediated disease in the subject and / or treats progression of a CD36-mediated disease in the subject. In some embodiments, the treatment method may further include administering one or more additional therapeutic agents or treatments known to those skilled in the art to prevent and / or treat a CD36-mediated disease or condition. Such methods including administration of one or more additional agents may encompass combined administration (wherein two or more therapeutic agents are included in the same or separate formulations) and separate administration, in which case administration of the antibody composition or formulation may be performed before, simultaneously with, and / or after administration of the additional therapeutic agent.
[0265] In some embodiments of the treatment methods of the present disclosure, an anti-CD36 antibody or a pharmaceutical formulation comprising an anti-CD36 antibody is administered to a subject by any administration method that delivers the agent systemically or to a desired target tissue. Systemic administration generally refers to any method of administering an antibody to a site in a subject other than directly to a desired target site, tissue, or organ, such that the antibody or its formulation enters the subject's circulatory system to undergo metabolism and other similar processes.
[0266] Therefore, the administration methods that can be used for the treatment methods of the present disclosure may include, but are not limited to, injection, infusion, instillation, and inhalation. Administration by injection may include intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, intracerebral spinal cord, and intrasternal injection and infusion.
[0267] In some embodiments, the pharmaceutical formulation of the anti-CD36 antibody is formulated such that the antibody is protected from inactivation in the intestinal tract. Thus, the method of treatment may comprise oral administration of the formulation.
[0268] In some embodiments, the use of a composition or formulation comprising an anti-CD36 antibody of the present disclosure as a medicament is also provided. In addition, in some embodiments, the present disclosure also provides the use of a composition or formulation comprising an anti-CD36 antibody in the manufacture or preparation of a medicament, particularly a medicament for treating, preventing or inhibiting a CD36-mediated disease. In a further embodiment, the medicament is a method for treating, preventing or inhibiting a CD36-mediated disease, the method comprising administering an effective amount of the medicament to an individual suffering from a CD36-mediated disease. In certain embodiments, the medicament further comprises an effective amount of at least one additional therapeutic agent or treatment.
[0269] In at least one embodiment, it is contemplated that additional therapeutic agents or treatments that can be used in such drugs together with the anti-CD36 antibodies of the present disclosure may include, but are not limited to, therapeutic antibodies comprising specificity for immune checkpoint molecules, such as PD1, PD-L1, LAG3, CTLA-4, A2AR, TIM-3, BTLA, CD276, CD328, VTCN1, IDO, KIR, NOX2, VISTA, OX40, CD27, CD28, CD40, CD122, CD137, GITR, ICOS. Exemplary antibodies comprising specificity for immune checkpoint molecules include, but are not limited to, anti-PD1 antibodies selected from dostatin, pembrolizumab, nivolumab, and pidilizumab.
[0270] In a further embodiment, the medicament is for treating, inhibiting or preventing a CD36-mediated disease, such as cancer, in a subject, and the method comprises administering to the subject an effective amount of the medicament to treat, inhibit or prevent a CD36-mediated disease.
[0271] The appropriate dosage of the anti-CD36 antibodies contained in the compositions and formulations of the present disclosure (when used alone or in combination with one or more other additional therapeutic agents) will depend on the specific disease or condition being treated, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapies administered to the patient, the patient's clinical history and response to the antibody, and the judgment of the attending physician. The anti-CD36 antibodies contained in the compositions and formulations described herein can be appropriately administered to the patient at one time or over a series of treatments. Various dosing regimens are contemplated herein, including, but not limited to, single or multiple administrations at different time points, bolus administration, and pulse infusions.
[0272] Depending on the type and severity of the disease, about 1 μg / kg to 15 mg / kg of anti-CD36 antibody in the formulation of the present disclosure is an initial candidate dose for administration to a human subject, whether, for example, by one or more separate administrations, or by continuous infusion. Typically, the antibody will be administered in a dose ranging from about 0.05 mg / kg to about 10 mg / kg. In some embodiments, one or more doses of about 0.5 mg / kg, 2.0 mg / kg, 4.0 mg / kg, or 10 mg / kg (or any combination thereof) may be administered to the patient.
[0273] Dosage administration may be maintained for several days or longer, depending on the subject's condition, e.g., administration may continue until the CD36-mediated disease is adequately treated, as determined by methods known in the art. In some embodiments, an initial higher loading dose may be administered, followed by one or more lower doses. However, other dosage regimens may be useful. The progression of the therapeutic effect of the dose administration may be monitored by conventional techniques and assays.
[0274] Thus, in some embodiments of the methods of the present disclosure, administration of an anti-CD36 antibody comprises a daily dose of from about 1 mg / kg to about 100 mg / kg. In some embodiments, the dose of an anti-CD36 antibody comprises a daily dose of at least about 1 mg / kg, at least about 5 mg / kg, at least about 10 mg / kg, at least about 20 mg / kg, or at least about 30 mg / kg.
[0275] Example
[0276] The various features and embodiments of the present disclosure are illustrated in the following representative examples, which are intended to be illustrative rather than limiting. Those skilled in the art will readily appreciate that the specific examples are only intended to illustrate the present invention, as more fully described in the subsequent claims. Each embodiment and feature described in this application should be understood to be interchangeable and combinable with each embodiment contained therein.
[0277] Example 1: Anti-CD36 Antibody Generation and CD36 Binding Analysis
[0278] This example illustrates the use of phage display antibody library technology to generate exemplary anti-CD36 antibodies of the present disclosure that specifically bind to human and mouse CD36.
[0279] A. Selection of anti-CD36 scFv binders from phage display antibody library
[0280] The screening procedure is briefly described below. First, human CD36.ECD antigen (5 μg per well, Sino Biological) in PBS buffer (pH 7.4) was coated on the wells of 96-well plates (NUNC Maxisorb immune plates) at 4 ° C overnight, and then blocked for 1 hour with 5% skim milk in PBST [0.1% (v / v) Tween 20]. After blocking, 100 μL of concentrated phage library (1013 cfu / mL in PBS buffer) was mixed with 100 μL blocking buffer and then added to each well for 1 hour under gentle shaking. The plate was washed 12 times with PBST and washed 3 times with PBS. The bound phage was eluted using 100 μL of 0.1M HCl / glycine (pH 2.2) / well and then immediately neutralized with 20 μL of 1M Tris-base buffer (pH 9.0). The eluted phages were mixed with 1 mL of E. coli ER2738 (A600 nm = 0.6) at 37°C for 30 minutes; uninfected bacteria were removed by adding ampicillin. After 30 minutes of ampicillin treatment, the bacterial culture was infected with 100 μL of M13KO7 helper phage (total ~1011 CFU) at 37°C for 1 hour, and then added to 50 mL of 2X YT medium containing 50 μg / mL of kanamycin and 100 μg / mL of ampicillin at 37°C and shaken vigorously overnight. The rescued phage library was precipitated with 20% polyethylene glycol / NaCl and resuspended in PBS. The concentrated phage solution was used for the next round of screening.
[0281] After 3-4 rounds of selection-amplification cycles, single colonies were randomly selected into deep-well 96-well culture plates (plate A; secreted scFv); each well contained 950 μL 2YT (100 μg / mL ampicillin). After shaking and incubating at 37°C for 3 hours, 50 μL of bacterial culture was transferred to the corresponding wells of a fresh deep-well 96-well plate (plate B; phage form); each well contained 0.8 mL 2YT with 100 μg / mL ampicillin. At the same time, 50 μL M13KO7 (total ~5×1010 CFU) was added to each well of plate B. After incubation for 1 hour, 100 μL of 2YT containing IPTG (10 mM) was added to each well of plate A; 100 μL of 2YT containing kanamycin (500 μg / mL) was added to each well of plate B. After incubation at 37°C with vigorous shaking overnight, the culture was centrifuged at 3000g for 10 minutes at 4°C. Plate B was saved for further sequencing assays. For the secretory scFv culture plate (plate A), 100 μL of culture medium and 100 μL of 5% PBST milk were added to the corresponding wells of three 96-well plates pre-coated with protein L (0.1 μg / well), human CD36 (0.5-1 μg / well) and bovine serum albumin (BSA) (2 μg / well), respectively, and blocked with 5% PBST milk. After incubation at room temperature for 1 hour, the plates were washed 3 times with PBST. 100 μL of protein A-HRP (Thermo Scientific) was added to each well of the protein L-coated immunoplate; 100 μL of anti-E tag HRP (ICL Inc.) was added to each well of the human CD36 antigen-coated and BSA-coated plates. After 1 hour incubation, the plates were washed three times with PBST buffer and twice with PBS, developed with 3,3',5,5'-tetramethylbenzidine peroxidase substrate (Kirkegaard & Perry Laboratories) for 3 minutes, quenched with 1.0 M HCl and read spectrophotometrically at 450 nm.
[0282] Positive clones were selected according to the following criteria: ELISA OD450>0.2 for wells coated with human CD36 antigen (antigen binding positive); OD450<0.05 for wells coated with BSA (non-specific binding negative); OD450>0.5 for wells coated with protein L (soluble scFv binds to both protein L and protein A to ensure correct folding in solution), and then DNA sequencing was performed. The polynucleotide sequence of the scFv of the exemplary anti-CD36 antibody 12P109 (SEQ ID NO: 1) obtained from the phage display screening is provided in Table 2 and the accompanying sequence listing. Further screening of a phage display library consisting of "shuffled" LC sequences derived from different anti-CD36 antibodies and the HC sequence of 12P109 provided the scFv of the exemplary anti-CD36 antibody A8A (SEQ ID NO: 10), which is also listed in Table 2 and the accompanying sequence listing. L The CDRs of the A8A-N52T domain (SEQ ID NO: 11) were further subjected to standard PCR-based mutagenesis to provide an exemplary anti-CD36 antibody VL domain of A8A-N52T (SEQ ID NO: 14), which is also listed in Table 2 and the accompanying sequence listing. B. Generation of full-length IgG anti-CD36 antibodies
[0283] scFv reformatting and cloning The CD36 binding determinants of the scFv selected from the phage display screening were removed by using the restriction enzyme sites MluI / NheI and BsiWI / DraIII to separate the V H and V L The domains were cloned into human IgG1-N297A heavy chain vector and human kappa light chain vector to reformat into full-length IgG antibody. The following forward and reverse oligonucleotide primer pairs were used to amplify V H and V L Domain: (1) PhageLib_VL_Fw :5'-AATCACgATgTgATATTCAAATgACCCAgAgCCCgAgC-3'(SEQ ID NO:64), (2)PhageLib_VL_Rv:5'-AATCgTACgTTTgATTTCCACTTTggTgCCTTg-3'(SEQ ID NO:65), (3) PhageLib_VH_Fw:5'-AATACgCgTgTCCTgTCCgAAgTgCAgCTggTggAATCg-3' (SEQ ID NO:66), and (4) PhageLib_VH_Rv:5'-AATgCTAgCCgAgCTCACggTAACAAg-3' (SEQ ID NO:67).
[0284] Expression and purification of full-length antibodies : Transient expression of the reformatted anti-CD36 antibody gene cloned vector in ExpiCHO-S cells (Thermo Scientific). During the exponential growth phase, ExpiCHO-S cells were diluted to a final density of 6 × 10 6 Cells / mL. ExpiFectamine CHO / plasmid DNA complexes were prepared using cold reagents according to the manual, incubated at room temperature for 1-5 minutes, and then slowly added to the cells. One day after transfection, the culture was supplemented with ExpiFectamine CHO enhancer and incubated for another 7 days. The transfected cell supernatant was centrifuged and then filtered through a 0.22 μm filter. Antibodies were purified from the transfected cell supernatant using protein A beads (Cytiva, 17127903). The antibody loading column was washed with 50 column volumes of PBS, and then eluted directly into 1 / 10 volume of 1M Tris buffer (pH 9.0) with 10 times the volume of beads of 0.1M glycine (pH 3). The eluate was buffer exchanged and concentrated with PBS (pH 7.4) containing 0.1M arginine. The quality of the purified anti-CD36 antibody was determined using SDS-PAGE with and without a reducing agent.
[0285] result : Examination of SDS-PAGE images showed that the expression and purification resulted in purified full-length anti-CD36 antibody.
[0286] C. Optimization of anti-CD36 antibody
[0287] To further improve the drugability of anti-CD36 antibody A8A, two phage display libraries consisting of mutations in N52, H91, and L94 were used for screening. The scFv clone 117 selected from the phage display screening was cloned into the V fragment of the fragment using the restriction enzyme sites MluI / NheI and BsiWI / DraIII, respectively. H and V L The domains were cloned into human IgG1-N297A heavy chain vector and human kappa light chain vector to reformat into full-length IgG antibody. The following forward and reverse oligonucleotide primer pairs were used to amplify V H and V L Domain: (1) PhageLib_VL_Fw:5'-AATCACgATgTgATATTCAAATgACCCAgAgCCCgAgC-3'(SEQ ID NO:64), (2)PhageLib_VL_Rv:5'-AATCgTACgTTTgATTTCCACTTTggTgCCTTg-3'(SEQ ID NO:65) (3) PhageLib_VH_Fw:5'-AATACgCgTgTCCTgTCCgAAgTgCAgCTggTggAATCg-3' (SEQ ID NO:66), and (4) PhageLib_VH_Rv:5'-AATgCTAgCCgAgCTCACggTAACAAg-3' (SEQ ID NO:67).
[0288] The CDR-H1, H2, H3 and CDR-L1 sequences of the 117 antibody are identical to those of A8A, and there is an N52T mutation in CDR-L2 and an L94A mutation in CDR-L3. The Fab fragment of the 117 antibody was also constructed into a human IgG4-S228P / F234A / L235A heavy chain vector using restriction enzyme sites NheI and BamHI. Further PCR-based mutagenesis was performed on the CDRs of the VH and VL domains of the 117 antibody to generate a series of variants, as summarized in Table 3 below.
[0289] Table 3
[0290]
[0291]
[0292]
[0293] As described above, the 117 antibody and variants were expressed and purified as full-length antibodies. Inspection of the SDS-PAGE images showed that the expression and purification resulted in purified full-length anti-CD36 antibodies. The amino acid sequences of the CDR, VH, VL, HC, LC regions of the 117 antibody and exemplary variants 117_30AA, 117_30DA, 117_57D, 117_57E and 117_DA57E are also listed in Table 2 and the accompanying sequence listing.
[0294] D. ELISA of anti-CD36 antibody specific binding to CD36
[0295] ELISA materials and methods:Recombinant His-tagged human CD36.ECD protein or His-tagged mouse CD36.ECD protein (both from Sino Biological) was fixed on a 96-well microtiter plate at a concentration of 1 μg / mL in a coating solution (SeraCare) overnight at 4°C. The wells were washed with a washing solution (0.05% Tween20 in PBS) and blocked with a 1% BSA in PBS solution. Serial dilutions of anti-CD36 antibodies were added to the wells. After incubation at 37°C for 1 hour, the wells were washed with a washing solution. A peroxidase-conjugated goat anti-human kappa light chain antibody (Sigma) was applied to each well and incubated at 37°C for 1 hour. After washing, the wells were developed with TMB substrate at room temperature for 5-10 minutes and then terminated with 1N HCl. The absorbance was then measured at 450nm and 650nm. EC50 values were calculated by GraphPad Prism7.
[0296] result : Figure 1A and Figure 1B ELISA data graphs showing binding of full-length IgG anti-CD36 antibody 12P109 and additional positive clones 12P102, 12P103, 12P104, 12P105, 12P106, 12P107, 12P110 and 12P212 to human CD36.ECD or mouse CD36.ECD are depicted, respectively. Binding curves for antibodies labeled 12P109, 12P103 and 12P212 show binding to human CD36 (hCD36, see Figure 1A ). 12P109 also showed the highest affinity for mouse CD36 (mCD36, see Figure 1B The EC50 values calculated from the ELISA data are shown in Table 4 below.
[0297] Table 4
[0298]
[0299] Figure 1C and 1D Depicted are ELISA data graphs showing the binding of anti-CD36 antibodies to recombinant human CD36.ECD or mouse CD36.ECD coated on ELISA plates, using anti-CD36 antibodies 12P109 and A8A in full-length human IgG1 format that specifically bind to CD36, and commercial mouse IgA antibody D2712 (clone CRF D-2712, BD Biosciences, US), respectively. Figure 1C and Figure 1D The EC50 values of the curves are shown in Table 5 below.
[0300] Table 5
[0301]
[0302] Figure 2A , Figure 2B , Figure 2C , Figure 2D , Figure 2E and Figure 2F Depicted are ELISA data graphs showing binding of full-length IgG anti-CD36 antibodies 12P109, 117, and each of the 117 variants listed in Table 3 to human CD36.ECD. Competitor anti-CD36 antibody ONA, derived from clone "ONA-0-v1" in the form of hIgG4-S228P-FALA as disclosed in WO2021176424A1. Figures 2A-2F The EC50 values calculated from the ELISA data are shown in Table 7 below.
[0303] Table 7
[0304]
[0305] F.SEC-UPLC analysis
[0306] The extended retention time (RT) of the antibody as determined by SEC-UPLC analysis may be related to non-specific hydrophobic interactions, which may create risks for the development of said antibodies for therapeutic use. Therefore, the anti-CD36 antibodies 12P109, A8A, 117 and 117 variants as well as IgG standards ("STD", BEH200 SEC protein standard mixture) and control monoclonal antibodies ("ctl Ab") were analyzed by SEC-UPLC for increased RT, which indicates the formation of protein aggregates.
[0307] Materials and methods : After protein A purification, protein aggregates and retention times of anti-CD36 antibodies 12P109, A8A, 117 and 117 variants were analyzed by standard size exclusion UPLC (SEC-UPLC). 3 μg of antibody was applied to UPLC (WatersARC UPLC) and separated using PBS mobile phase on a gel filtration column (Waters, Xbridge BEH450 SEC 4.6×150). The antibody peak UV absorbance was monitored at 280 and the peak area was determined using Empower software.
[0308] result : SEC-UPLC results are shown in Figure 3A , Figure 3B , Figure 3C , Figure 3D3E, the RT values of the assay are shown together. The control antibody showed an RT value of 7.243 minutes, while the anti-CD36 antibodies 12P109 and 117 all showed a relatively increased RT value. However, the increased RT value of 117 was significantly reduced due to the mutations present in variants 117_30DA, 117_31AD, 117_57D, 117_57E, 117_57EE, 117_101D and 117_DA57E. The RT values of the anti-CD36 antibodies as measured in the SEC-UPLC experiment are provided in Table 8 below. In addition, some aggregates were found in 117_DA57E by UPLC analysis. Aggregates may be related to the fact that 117_DA57E is not very stable to acidic elution conditions. The R409K mutation in IgG4 has been shown to increase the CH3 domain interaction strength and reduce the trend of aggregation at low pH. SEC-UPLC analysis showed that the addition of R409K to 117_DA57E reduced aggregation caused by acidic conditions.
[0309] Table 8
[0310]
[0311]
[0312] G. BLI analysis of CD36 binding kinetics
[0313] Materials and methods for BLI experiments : The kinetic rate constants ka and kd of the binding of anti-CD36 antibodies to human CD36 were measured by biolayer interferometry (BLI) (ForteBio Octet RED96). BLI assays were performed using an AHC (anti-hIgG Fc capture) biosensor (ForteBio) to capture each anti-CD36 antibody (5 μg / mL) to obtain a 0.5 nm shift, and then the biosensor was immersed in varying concentrations (i.e., 0, 1.5625, 3.125, 6.25, 4.94, 12.5, 25, 50, and 100 nM) of recombinant His-tagged human CD36.ECD protein (Sino Biological) in running buffer containing 0.1% BSA, 0.1% Tween-20, 250 mM NaCl in PBS. The rate constants were calculated by curve fitting analysis of the binding reaction (1:1 Langmuir model) as 2.5 minutes of binding interaction time and 5 minutes of dissociation interaction time.
[0314] resultTable 10 below provides the determined dissociation constant KD and kinetic rate constants ka and kd for binding of anti-CD36 antibodies 12P109, A8A, 117 and various 117 variants (in IgG1 or IgG4 format) to human CD36 as determined in separate BLI analysis experiments.
[0315] Table 10
[0316]
[0317]
[0318] Example 2: Binding of anti-CD36 antibodies to CD36 expressed on the cell surface
[0319] This example describes the preparation of stable F293 cell lines that overexpress hCD36 or mCD36 on the cell surface, and studies to determine the binding affinity of exemplary anti-CD36 antibodies of the present disclosure to human, rhesus monkey or mouse CD36 expressed on the cell surface.
[0320] A. Generation of a stable F293 cell line overexpressing CD36
[0321] Materials and methods:The gene fragments encoding full-length human CD36-Flag (Sino Biological), rhesus CD36-His (Sino Biological) and mouse CD36-His (Sino Biological) were subcloned into pcDNA3.4 topology vectors using XbaI / HindIII. Freestyle 293-F cells (Thermo Scientific) were transfected with plasmids encoding CD36 by the polyethyleneimine (PEI) method and selected with geneticin (Thermo Scientific) to establish a CD36 stable cell pool. The expression of human CD36 was verified by surface staining of anti-CD36 (clone 5-271, Biolegend) or by intracellular staining of anti-FLAG. The expression of rhesus CD36 was verified by surface staining of anti-CD36 clone 117 or by intracellular staining of anti-His. The expression of mouse CD36 was verified by surface staining of anti-CD36 antibody D2712 (clone CRF D-2712; BD Biosciences, US) or by intracellular staining of anti-His. To enrich for stable cell lines expressing CD36, pools of F293 cells overexpressing hCD36, rhesus CD36, or mCD36 were stained with anti-CD36 (clone 5-271, Biolegend), anti-CD36 clone 117, or anti-CD36 D2712 (clone CRF D-2712, BD Biosciences), respectively. High CD36 cell populations were selected by FACSAriaIIIu (BD).
[0322] result : Analysis of FACS data confirmed that stable F293 cells F293 / hCD36, F293 / rhesus CD36 and F293 / mCD36 overexpressed surface CD36 that was able to bind to anti-CD36 antibodies.
[0323] B. Cell surface CD36 binding activity of anti-CD36 antibodies
[0324] Materials and methods : F293 cells that highly express CD36 as described in Section A above were incubated with a series of dilutions of anti-CD36 antibodies 117 and several variants of 117 (see Table 3) at 4° C. for 30 minutes. After washing with FACS buffer (2% FBS in PBS), the cells were stained with anti-human IgG-Alexa Fluor 647 and analyzed by Attune NxT flow cytometer (Thermo Scientific).
[0325] result: Analysis of flow cytometry data expressed as geometric mean (MFI) demonstrated that anti-CD36 antibodies specifically bind to cells expressing hCD36 and mCD36 on their surface.
[0326] Figure 4A , Figure 4B , Figure 4C , Figure 4D and Figure 4E Depicted in Figure 5 are graphs showing data showing binding of the full-length IgG anti-CD36 antibody 117 and several 117 variants to the surface of F293 cells expressing human, rhesus monkey, or mouse CD36. Figures 4A-4E EC of the curve 50 The values are shown in Table 11 below.
[0327] Table 11
[0328]
[0329] Example 3: Anti-CD36 Antibody's Oxidized LDL Uptake Blocking Activity
[0330] This example describes studies that determined the ability of exemplary anti-CD36 antibodies of the present disclosure to block oxidized LDL uptake by cells expressing CD36.
[0331] A. Inhibition of oxidized LDL binding and uptake in U937 cells by anti-CD36 antibodies
[0332] U937 cells that highly express CD36 were preincubated with control IgG or anti-CD36 antibody for 30 minutes at 4°C. To measure the binding or uptake of oxLDL, Dil-oxLDL (5-10 μg / mL) (Cat. No. 770232-9; Kalen Biomedical), a purified human LDL that has been oxidized with copper (II) sulfate and labeled with "Dil" (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocyanine perchlorate) was added to serum-free medium and incubated at 4°C for 2 hours or at 37°C for 5 minutes, respectively. After washing with PBS, the cells were analyzed by Attune NxT flow cytometer (Thermo Scientific).
[0333] It was observed that binding of the anti-CD36 antibodies of the present disclosure to U937 cells resulted in a characteristic shift, confirming the endogenous expression of surface CD36 by U937. Analysis of the extracted U937 flow cytometry data confirmed that when incubated with the anti-CD36 antibodies 12P103, 12P110 or 12P109 of the present disclosure, oxLDL binding of U937 cells was increased ( Figure 5A ) and oxLDL uptake ( Figure 5B ) has decreased.
[0334] B. Inhibition of uptake of oxidized LDL in F293 / CD36 cells by anti-CD36 antibodies F293 / hCD36 cells were pre-incubated with control IgG or anti-CD36 antibodies for 30 minutes at 4°C. To measure the binding or uptake of oxLDL, Dil-oxLDL (5 μg / mL) (Kalen Biomedical) was added to serum-free medium and incubated at 4°C for 2 hours to measure "oxLDL binding" or at 37°C for 5 minutes to measure "oxLDL uptake", respectively. After washing with PBS, the cell preparations were analyzed using an Attune NxT flow cytometer (Thermo Scientific).
[0335] result :like Fig. 6A , Figure 6B and Figure 6C As shown in the flow cytometry data graph depicted in FIG, the presence of anti-CD36 antibodies 12P109, 117, 117_30DA, 117_57D, 117_57E, 117_30DE, 117_57EE, 117_DA57D or 117_DA57E effectively blocked oxidized LDL uptake by F293 cells overexpressing human CD36 on their surface. Figure 6C As shown in the figure, the presence of anti-CD36 antibodies 12P109, 117_30DA, 117_57D or 117_57E effectively blocked oxLDL uptake by F293 cells overexpressing mouse CD36 on their surface. The IC values of these anti-CD36 antibodies for inhibiting oxLDL uptake by F293 / hCD36 or F293 / mCD36 cells were determined. 50 The values are shown in Table 13 below.
[0336] Table 13
[0337]
[0338] Example 4: Activity of anti-CD36 antibodies in blocking oxLDL uptake by TILs
[0339] This example describes the study of anti-CD36 antibodies blocking the uptake of oxidized LDL in mouse tumor-infiltrating lymphocytes (TILs).
[0340] Materials and methods Mouse colon cancer cell line CT-26 (2×10 5 cells, ATCC number: CRL-2638) or mouse hepatoma cell line BNL 1MEA.7R.1 (5×10 61×10 cells, ATCC number: TIB-75) were injected subcutaneously into the right flank of BALB / c mice. 6 cells, Kerafast #ENH204-FP), mouse melanoma cell line B16-F10 (1×10 6 cells, BCRC#60031) or mouse lung cancer cell line LL / 2 (2×10 5 Cells, BCRC # 60050) were injected subcutaneously into the right flank of C57BL / 6 mice. CT-26 tumors were harvested 4 weeks later. B16-F10, BNL1MEA.7R.1, MC38 and LL / 2 tumors were harvested 2 weeks later. Tumor cell suspensions were prepared from solid tumors using a mouse tumor isolation kit (Miltenyi Biotec) according to the manufacturer's instructions. CD45 microbeads (Miltenyi Biotec) were used to isolate CD45+ TILs from tumor cell suspensions.
[0341] Isolated CD45+TILs were pre-incubated with control IgG or anti-CD36 antibody (5-10 μg / mL) at 4°C for 30 minutes. Dil-oxLDL (5-10 μg / mL) was added to RPMI medium containing 1% fatty acid-free BSA and incubated at 37°C for 15 minutes. After washing with PBS, cells were analyzed by Attune NxT flow cytometer (Thermo Scientific). The binding and uptake of oxLDL were analyzed by flow cytometry and expressed as percentage (%) positive cells based on histogram gating placed on negative control cells.
[0342] Data are presented as mean ± SD. *p < 0.05, **p < 0.005, one-way ANOVA.
[0343] result :like Fig. 7A As shown in the results graph depicted in , the anti-CD36 antibodies 12P109 and A8A of the present disclosure that specifically bind to hCD36 and mCD36 provide about 35% inhibition of oxLDL uptake in CD45+ TILs isolated from CT26 tumors injected into BALB / c mice. The level of inhibition is equivalent to that observed in the commercially available antibody D2712 that specifically binds to mouse CD36.
[0344] like Figure 7B , Figure 7C , Fig.7D and Fig. 7EAs shown in the result graph depicted in , anti-CD36 antibodies 117_57E, 117_30DA, 117_57DE and 117_DA57E showed inhibitory activity on oxLDL uptake in CD45+ TILs from B16-F10, BNL 1MEA.7R.1, MC38 and LL / 2 tumors.
[0345] Example 5: M2 macrophage polarization and activation blocking activity
[0346] This study was performed to determine the ability of the anti-CD36 antibodies of the present disclosure to inhibit M2 macrophage polarization and activation.
[0347] Materials and methods To generate monocyte-derived macrophages, human CD14+ monocytes were isolated from PBMCs and cultured at 2×10 in RPMI1640 supplemented with 10% FBS and 20 ng / ml CSF1. 6 Cells / ml were cultured for 6 days. The adhered macrophages were then collected by EDTA separation and seeded in 24-well plates for further polarization. For M0 macrophages, cells were cultured in culture medium for 2 days. In order to polarize M2 macrophages, macrophages were cultured for another 2 days in a culture medium containing 50ng / mL IL-4 and 50ng / mL IL-13. 10 μg / mL control IgG or anti-CD36 antibodies were added during M2 macrophage polarization. For oxLDL activation, macrophages were pre-incubated with control IgG or anti-CD36 antibodies for 10 minutes, and then cultured for another 2 days in M2 culture medium containing 10 μg / mL oxLDL (Kalen Biomedical). In order to detect M2 macrophage activation, macrophages were harvested and stained with antibodies against CD206, CD301 and PDL2. The level of surface markers was analyzed by Attune NxT flow cytometer (ThermoScientific).
[0348] result :like Fig. 8A and Figure 8B As shown in the data graph depicted in FIG, anti-CD36 antibody 117_30AA has a strong affinity for CD206+ / CD301+( Fig. 8A ) and CD206+ / PDL2+( Figure 8B ) double positive cell populations showed very strong inhibition of M2 macrophage polarization. Figure 8C , Fig.8D , Fig. 8E and Figure 8F As shown in the data graph depicted in FIG, anti-CD36 antibodies 117_30DA, 117_57D, 117_57E and 117_DA57E have an inhibitory effect on CD206+ / CD301+( Figure 8C , Fig.8D ) and CD206+ / PDL2+( Fig. 8E , Figure 8F ) double positive cell populations showed very strong inhibition of oxLDL-induced M2 macrophage activation. Fig.8D and Figure 8F As shown in the data graphs depicted in , anti-CD36 antibodies 117_30DA and 117_DA57E exhibited very strong inhibition of oxLDL-induced M2 macrophage activation compared to the IgG control and competitor anti-CD36 antibody "ONA", which is a Fab clone "ONA-0-v1" with a hIgG4-S228P-FALA Fc region as disclosed in WO2021176424A1.
[0349] Example 6: Activity of anti-CD36 antibodies in a mouse hepatocellular carcinoma model
[0350] This example describes the study of the activity of anti-CD36 antibodies in inhibiting tumor growth in two genetically induced hepatocellular carcinoma (HCC) mouse models: (1) transgenic HCC induced by overexpression of MYC-luc-ova and knockout of p53 mediated by the Sleeping Beauty transposon (SB100x) system; and (2) transgenic HCC induced by overexpression of MYC-luc-ova and knockout of β-catenin mediated by the Sleeping Beauty transposon (SB100x) system. N90 of transgenic-induced HCC.
[0351] Materials and methods
[0352] Six-week-old mice were restrained and hydrodynamically delivered with endotoxin-free plasmid DNA via the lateral tail vein injection in a volume equivalent to 10% of body weight within 5-7 seconds. OE / p53 KO HCC model, pT3-Myc-luc-ova plasmid (Addgene#129776), p53 gRNA plasmid (Addgene#59910), and SB100x (a plasmid containing transposase; Addgene#34879) were injected into mice. For β-catenin / Myc (β-catenin OE / MYC OE )HCC model, pT3-bcatenin (Addgene #31785), pT3-Myc-luc-ova plasmid and SB100x were injected into each mouse. β-catenin driven liver tumors represent a more aggressive HCC with a cold tumor phenotype.
[0353] To monitor tumor growth, luciferin (150 mg / Kg) was injected into mice and bioluminescent activity was analyzed in an IVIS imaging system. Mice with persistent tumor growth were randomized and administered anti-CD36 antibody (10 mg / kg) or PBS (control) by intraperitoneal injection as described below.
[0354] After 2 weeks, MYC OE / p53 KO HCC model mice were intraperitoneally injected with 4 doses of anti-CD36 antibody (10 mg / kg; clone: 117_30DA) or control antibody every 3 days, and bioluminescence imaging of the mice was measured in an IVIS system every 6 days (n=5 per group).
[0355] After 3 weeks, β-catenin OE / MYC OE HCC model mice were intraperitoneally injected with anti-CD36 antibody (10 mg / mL, clone: 117_DA57E) or control antibody (n=6 per group), and bioluminescence imaging of the mice was measured in an IVIS system every 5 days.
[0356] In β-catenin OE / MYC OE In the HCC model, tumors showed aggressive progression and tumor-bearing mice usually died 38 days after hydrodynamic injection. Therefore, tumors were harvested and weighed 35-38 days after hydrodynamic tail vein injection.
[0357] result
[0358] Fig. 9 showed that after treatment with the anti-CD36 antibody 117_30DA, MYC OE / p53 KO Tumor growth curves measured by bioluminescence in HCC model mice. Starting from 14 days after HCC induction and continuing until 38 days, significant inhibition of tumor growth was observed in treated mice compared with the control group. P value = 0.0114, t-test, two-tailed.
[0359] Fig. 10A showed that after treatment with the anti-CD36 antibody 117_DA57E, there was a significant decrease in the expression of β-catenin OE / MYC OE Tumor growth curves measured by bioluminescence in HCC model mice. Starting from 21 days after HCC induction and continuing until 36 days, significant inhibition of tumor growth was observed in treated mice compared with the control group. P value = 0.0104, t-test, two-tailed. Fig. 10Bshowed that the endpoint liver weight was significantly reduced in mice treated with anti-CD36. Fig. 10C As shown, analysis of plasma ALT (alanine transaminase) activity indicated that anti-CD36 treatment also alleviated liver damage caused by cancer development.
[0360] Although the above disclosure of the present invention has been described in detail by way of example and illustration for the purpose of clarity and understanding, the present disclosure including the examples, descriptions and embodiments described herein is for illustrative purposes and is intended to be used as examples and should not be construed as limiting the present disclosure. It will be clear to those skilled in the art that various modifications or changes may be made to the embodiments, descriptions and embodiments described herein, and these modifications or changes should be included in the spirit and scope of the present disclosure and the appended claims. In addition, those skilled in the art will recognize a large number of methods and procedures equivalent to the methods and procedures described herein. All such equivalents should be understood to be within the scope of the present disclosure and covered by the appended claims.
[0361] Other embodiments of the invention are set forth in the following claims.
[0362] The disclosures of all publications, patent applications, patents, or other documents mentioned herein are expressly incorporated by reference in their entirety for all purposes to the same extent as if each such individual publication, patent, patent application, or other document was individually and specifically indicated to be incorporated by reference in its entirety for all purposes and was set forth in its entirety herein. In the event of a conflict, the present specification, including designated terms, will control.
[0363] References
[0364] Al-Khami, AA et al. (2017). Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. Oncoimmunology 6:e1344804, doi:10.1080 / 2162402X.2017.1344804.
[0365] Almeida,P.E.et al.(2014).Differential TLR2 downstream signalingregulates lipid metabolism and cytokine production triggered by Mycobacteriumbovis BCG infection.Biochim.Biophys.Acta.1841:97-107,doi:10.1016 / j.bbalip.2013.10.008.
[0366] Aloia,A.et al.(2019).A fatty acid oxidation-dependent metabolic shiftregulates the adaptation of BRAF-mutated melanoma to MAPKinhibitors.Clin.Cancer Res.25:6852,doi:10.1158 / 1078-0432.CCR-19-0253.
[0367] Barrett,L.et al.(2007).Circulating CD14-CD36+peripheral bloodmononuclear cells constitutively produce interleukin-10.J.Leukoc.Biol.82:152-60,doi:10.1189 / jlb.0806521.
[0368] Chung,E.Y.et al.(2007).Interleukin-10 expression in macrophagesduring phagocytosis of apoptotic cells is mediated by homeodomain proteinsPbx1 and Prep-1.Immunity 27:952-964,doi:10.1016 / j.immuni.2007.11.014.
[0369] Enciu,A.-M.et al.(2018).Targeting CD36 as biomarker for metastasisprognostic:how far from translation into clinical practice?Biomed.Res.Int.2018:7801202,doi:10.1155 / 2018 / 7801202.
[0370] Feng,W.W.et al.(2019).CD36-mediated metabolic rewiring of breastcancer cells promotes resistance to HER2-targeted therapies.Cell Reports 29:3405-20,doi:10.1016 / j.celrep.2019.11.008.
[0371] Goedegebuure,P.et al.(2011).Myeloid-derived suppressor cells:generalcharacteristics and relevance to clinical management of pancreaticcancer.Curr.Cancer Drug Targets 11:734-51,doi:10.2174 / 156800911796191024.
[0372] Hale,J.S.et al.(2014).Cancer stem cell-specific scavenger receptorCD36 drives glioblastoma progression.Stem Cells 32:1746-58,doi:10.1002 / stem.1716.
[0373] Huang,S.C.et al.(2014).Cell-intrinsic lysosomal lipolysis isessential for alternative activation of macrophages.Nature Immunol.15:846-55,doi:10.1038 / ni.2956.
[0374] Joyce,J.A.&Pollard,J.W.(2009).Microenvironmental regulation ofmetastasis.Nature Reviews Cancer 9:239-52,doi:10.1038 / nrc2618.
[0375] Kuda,O.et al.(2011).CD36 protein is involved in store-operatedcalcium flux,phospholipase A2 activation,and production of prostaglandinE2.J.Biol.Chem.286:17785-95,doi:10.1074 / jbc.M111.232975.
[0376] Lewis,C.E.&Pollard,J.W.(2006).Distinct role of macrophages indifferent tumor microenvironments.Cancer Res.66:605-12,doi:10.1158 / 0008-5472.CAN-05-4005.
[0377] Liang,Y.et al.(2018).CD36 plays a critical role in proliferation,migration and tamoxifen-inhibited growth of ER-positive breast cancercells.Oncogenesis 7:98,doi:10.1038 / s41389-018-0107-x.
[0378] Ma,X.et al.(2021).CD36-mediated ferroptosis dampens intratumoral CD8+T cell effector function and impairs their antitumor ability,Cell Metabolism33:1-12,doi:10.1016 / j.cmet.2021.02.015.
[0379] Mizuno,R.et al.(2019).Prostaglandin E2 / EP signaling in the tumormicroenvironment of colorectal cancer.Int.J.Mol.Sci.20:6254,doi:10.3390 / ijms20246254.
[0380] Nath,A.et al.(2015).Elevated free fatty acid uptake via CD36 promotesepithelial-mesenchymal transition in hepatocellular carcinoma.Sci.Rep.5:14752,doi:10.1038 / srep14752.
[0381] Oh,J.et al.(2012).Endoplasmic reticulum stress controls M2 macrophagedifferentiation and foam cell formation.J.Biol.Chem.287:11629-41,doi:10.1074 / jbc.M111.338673.
[0382] Oh,K.et al.(2013).A mutual activation loop between breast cancercells and myeloid-derived suppressor cells facilitates spontaneous metastasisthrough IL-6 trans-signaling in a murine model.Breast Cancer Research 15:R79,doi:10.1186 / bcr3473.
[0383] Pascual,G.et al.(2017).Targeting metastasis-initiating cells throughthe fatty acid receptor CD36.Nature 541:41-45,doi:10.1038 / nature20791.
[0384] Pepino,Y.M.et al.(2014).Structure-function of CD36 and importance offatty acid signal transduction in fat metabolism.Annu.Rev.Nutr.34:281-303,doi:10.1146 / annurev-nutr-071812-161220.
[0385] Pepper,M.S.et al.(2003).Lymphangiogenesis and tumor metastasis.CellTissue Res 314:167–77,doi:10.1007 / s00441-003-0748-7.
[0386] Pollard,J.W.(2008).Macrophages define the invasive microenvironmentin breast cancer.J.Leukoc.Biol.84:623–30,doi:10.1189 / jlb.1107762.
[0387] Psaila,B.&Lyden,D.(2009).The metastatic niche:adapting the foreignsoil.Nature Reviews Cancer 9:285–93,doi:10.1038 / nrc2621.
[0388] Rada,P.et al.(2020).Understanding lipotoxicity in NAFLD pathogenesis:is CD36 a key driver?Cell Death and Disease 11:802,doi:10.1038 / s41419-020-03003-w.
[0389] Su,P.et al.(2020).Enhanced lipid accumulation and metabolism arerequired for the differentiation and activation of tumor-associatedmacrophages.Cancer Res.80:1438-50,doi:10.1158 / 0008-5472.CAN-19-2994.
[0390] Sugimoto,Y.et al.(1993).Molecular cloning and characterization of thecomplementary DNA for the Mr 85,000 protein overexpressed in adriamycin-resistant human tumor cells.Cancer Res.53:2538-43.
[0391] Wang,D.&Dubois,R.N.(2006).Prostaglandins and cancer.Gut 55:115-22,doi:10.1136 / gut.2004.047100.
[0392] Wang,J.&Li,Y.(2019).CD36 tango in cancer:signaling pathways andfunctions.Theranostics 9:4893-908,doi:10.7150 / thno.36037.
[0393] Wang,H.et al.(2020).CD36-mediated metabolic adaptation supportsregulatory T cell survival and function in tumors.Nat.Immunol.21:298–308,doi:10.1038 / s41590-019-0589-5.
[0394] Watt,M.J.et al.(2019).Suppressing fatty acid uptake has therapeuticeffects in preclinical models of prostate cancer.Sci.Transl.Med.11:eaau5758,doi:10.1126 / scitranslmed.aau5758.
[0395] Whiteside,T.L.&Jackson,E.K.(2013).Adenosine and prostaglandin e2production by human inducible regulatory T cells in health anddisease.Frontiers Immunol.4:212,doi:10.3389 / fimmu.2013.00212.
[0396] Wu,K.et al.(2020).Redefining tumor-associated macrophagesubpopulations and functions in the tumor microenvironment.Front.Immunol.11:1731,doi:10.3389 / fimmu.2020.01731.
[0397] Xu,S.et al.(2020).Oxidized lipids and CD36-mediated lipidperoxidation in CD8 T cells suppress anti-tumor immune responses.BioRxivpreprint doi:10.1101 / 2020.09.03.281691.
[0398] Xu,S.et al.(2021).Uptake of oxidized lipids by the scavenger receptorCD36 promotes lipid peroxidation and dysfunction in CD8+T cells intumors.Immunity 54(7):1561-1577.e7,doi:10.1016 / j.immuni.2021.05.003.
[0399] Ye,H.et al.(2016).Leukemic stem cells evade chemotherapy by metabolicadaptation to an adipose tissue niche.Cell Stem Cell 19:23–37,doi:10.1016 / j.stem.2016.06.001.
[0400] Zeisberger,S.M.et al.(2006).Clodronate-liposome-mediated depletion oftumour-associated macrophages:a new and highly effective antiangiogenictherapy approach.British J.Cancer 95:272-81,doi:10.1038 / sj.bjc.6603240.
[0401] Zhao,L.et al.(2018).CD36 and lipid metabolism in the evolution ofatherosclerosis.British Medical Bulletin 126:101–112,10.1093 / bmb / ldy006.
Claims
1. An anti-CD36 antibody comprising (i) a first heavy chain complementary determining region (CDR-H1), a second heavy chain complementary determining region (CDR-H2), and a third heavy chain complementary determining region (CDR-H3), and (ii) a first light chain complementary determining region (CDR-L1), a second light chain complementary determining region (CDR-L2), and a third light chain complementary determining region (CDR-L3), in: (a) CDR-H1 comprises the amino acid sequence of SEQ ID NO: 24, 3, 21 or 27; (b) CDR-H2 comprises the amino acid sequence of SEQ ID NO: 43, 4, 28, 31, 34, 37 or 40; (c) CDR-H3 comprises the amino acid sequence of SEQ ID NO: 5; (d) CDR-L1 comprises an amino acid sequence selected from SEQ ID NO: 7; (e) CDR-L2 comprises an amino acid sequence selected from SEQ ID NO: 15, 8 or 12; and (f) CDR-L3 comprises an amino acid sequence selected from SEQ ID NO: 18, 9 or 13.
2. The antibody according to claim 1, in: (a) CDR-H1 comprises the amino acid sequence of SEQ ID NO:24, CDR-H2 comprises the amino acid sequence of SEQ ID NO:43, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18; (b) CDR-H1 comprises the amino acid sequence of SEQ ID NO:3, CDR-H2 comprises the amino acid sequence of SEQ ID NO:4, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:8, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:9; (c) CDR-H1 comprises the amino acid sequence of SEQ ID NO:3, CDR-H2 comprises the amino acid sequence of SEQ ID NO:4, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:12, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:13; (d) CDR-H1 comprises the amino acid sequence of SEQ ID NO:3, CDR-H2 comprises the amino acid sequence of SEQ ID NO:4, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:13; (e) CDR-H1 comprises the amino acid sequence of SEQ ID NO:3, CDR-H2 comprises the amino acid sequence of SEQ ID NO:4, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18; (f) CDR-H1 comprises the amino acid sequence of SEQ ID NO:21, CDR-H2 comprises the amino acid sequence of SEQ ID NO:4, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18; (g) CDR-H1 comprises the amino acid sequence of SEQ ID NO:24, CDR-H2 comprises the amino acid sequence of SEQ ID NO:4, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18; (h) CDR-H1 comprises the amino acid sequence of SEQ ID NO:27, CDR-H2 comprises the amino acid sequence of SEQ ID NO:28, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18; (i) CDR-H1 comprises the amino acid sequence of SEQ ID NO:3, CDR-H2 comprises the amino acid sequence of SEQ ID NO:31, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18; (j) CDR-H1 comprises the amino acid sequence of SEQ ID NO:3, CDR-H2 comprises the amino acid sequence of SEQ ID NO:34, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18; (k) CDR-H1 comprises the amino acid sequence of SEQ ID NO:3, CDR-H2 comprises the amino acid sequence of SEQ ID NO:37, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:18; or (l) CDR-H1 comprises the amino acid sequence of SEQ ID NO:3, CDR-H2 comprises the amino acid sequence of SEQ ID NO:40, CDR-H3 comprises the amino acid sequence of SEQ ID NO:5, CDR-L1 comprises the amino acid sequence of SEQ ID NO:7, CDR-L2 comprises the amino acid sequence of SEQ ID NO:15, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:
18.
3. An anti-CD36 antibody comprising: (i) a first heavy chain complementarity determining region (CDR-H1), a second heavy chain complementarity determining region (CDR-H2), and a third heavy chain complementarity determining region (CDR-H3), wherein the sequences of CDR-H1, CDR-H2, and CDR-H3 are from a VH region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 42, 2, 20, 23, 26, 30, 33, 36, and 39; (ii) a first light chain complementary determining region (CDR-L1), a second light chain complementary determining region (CDR-L2), and a third light chain complementary determining region (CDR-L3), wherein the sequences of CDR-L1, CDR-L2, and CDR-L3 are from a VL region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 17, 6, 11, and 14, and The CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 are numbered according to Kabat.
4. The antibody according to claim 3, in: (a) the VH amino acid sequence is SEQ ID NO:42 and the VL amino acid sequence is SEQ ID NO:17; (b) the VH amino acid sequence is SEQ ID NO: 2 and the VL amino acid sequence is SEQ ID NO: 6; (c) the VH amino acid sequence is SEQ ID NO: 2 and the VL amino acid sequence is SEQ ID NO: 11; (d) the VH amino acid sequence is SEQ ID NO: 2 and the VL amino acid sequence is SEQ ID NO: 14; (e) the VH amino acid sequence is SEQ ID NO: 2 and the VL amino acid sequence is SEQ ID NO: 17; (f) the VH amino acid sequence is SEQ ID NO: 20 and the VL amino acid sequence is SEQ ID NO: 17; (g) the VH amino acid sequence is SEQ ID NO:23 and the VL amino acid sequence is SEQ ID NO:17; (h) the VH amino acid sequence is SEQ ID NO:26 and the VL amino acid sequence is SEQ ID NO:17; (i) the VH amino acid sequence is SEQ ID NO: 30 and the VL amino acid sequence is SEQ ID NO: 17; (j) the VH amino acid sequence is SEQ ID NO:33 and the VL amino acid sequence is SEQ ID NO:17; (k) the VH amino acid sequence is SEQ ID NO:36 and the VL amino acid sequence is SEQ ID NO:17; or (l) The VH amino acid sequence is SEQ ID NO:39 and the VL amino acid sequence is SEQ ID NO:
17.
5. The antibody of any one of claims 1-4, wherein the antibody comprises a heavy chain variable domain (V H ) that is at least 90% identical to a sequence selected from SEQ ID NO: 42, 2, 20, 23, 26, 30, 33, 36 or 39. H ) amino acid sequence; and a light chain variable domain (V L ) amino acid sequence.
6. The antibody according to any one of claims 1 to 4, in: (a) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 42 H The amino acid sequence is at least 90% identical to SEQ ID NO:
17. L Amino acid sequence; (b) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 2 H The amino acid sequence is at least 90% identical to SEQ ID NO:
6. L Amino acid sequence; (c) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 2 H The amino acid sequence is at least 90% identical to SEQ ID NO:
11. L Amino acid sequence; (d) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 2 H The amino acid sequence is at least 90% identical to SEQ ID NO:
14. L Amino acid sequence; (e) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 2 H The amino acid sequence is at least 90% identical to SEQ ID NO:
17. L Amino acid sequence; (f) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 20 H The amino acid sequence is at least 90% identical to SEQ ID NO:
17. L Amino acid sequence; (g) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 23 H The amino acid sequence is at least 90% identical to SEQ ID NO:
17. L Amino acid sequence; (h) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 26 H The amino acid sequence is at least 90% identical to SEQ ID NO:
17. L Amino acid sequence; (i) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 30 H The amino acid sequence is at least 90% identical to SEQ ID NO:
17. L Amino acid sequence; (j) the antibody comprises a VH amino acid sequence that is at least 90% identical to SEQ ID NO: 33 and a VH amino acid sequence that is at least 90% identical to SEQ ID NO: 17 L Amino acid sequence; (k) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 36 H The amino acid sequence is at least 90% identical to SEQ ID NO:
17. L Amino acid sequence; or (l) the antibody comprises a V sequence that is at least 90% identical to SEQ ID NO: 39 H The amino acid sequence is at least 90% identical to SEQ ID NO:
17. L Amino acid sequence.
7. An antibody according to any one of claims 1-4, wherein the antibody comprises a heavy chain (HC) amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NO: 57, 44, 48, 50, 51, 52, 53, 54, 55 or 56, and / or a light chain (LC) amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NO: 49, 45, 46 or 47.
8. The antibody according to any one of claims 1 to 4, wherein the antibody comprises: (a) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:57, and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49; (b) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:44, and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:45; (c) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:44, and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:46; (d) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:44, and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:47; (e) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:44, and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49; (f) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:48, and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49; (g) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:50, and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49; (h) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:51, and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49; (i) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:52, and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49; (j) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:53, and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49; (k) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:54, and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49; (l) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:55, and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:49; or (m) a HC amino acid sequence that is at least 90% identical to SEQ ID NO:56, and a LC amino acid sequence that is at least 90% identical to SEQ ID NO:
49.
9. The antibody according to any one of claims 1 to 4, wherein the antibody: (a) is an antibody fragment, optionally selected from F(ab') 2 , Fab', Fab, Fv, single domain antibody (VHH) and scFv; (b) comprising a fusion with a protein; optionally, wherein the protein is an immunostimulatory cytokine selected from IL-2, IL-7, IL-10, IL-12, IL-15, IL-21 or IFN-α; (c) a human antibody, a humanized antibody or a chimeric antibody; (d) is a full length antibody of the IgG class, optionally, wherein the IgG class antibody has an isotype selected from IgG1, IgG2, IgG3 and IgG4; (e) comprising an Fc region variant, optionally comprising an Fc region variant with altered effector function and / or a variant that alters the half-life of the antibody; (f) comprising an immunoconjugate, optionally wherein the immunoconjugate comprises a therapeutic agent for treating a CD36-mediated disease or condition; and / or (g) is a multispecific antibody; optionally, is a bispecific antibody.
10. The antibody according to any one of claims 1 to 9, in: (a) The antibody was expressed at 1×10 -8 M or less, 1×10 -9 M or less, 1×10 -10 M or less binding affinity to human CD36; optionally, wherein the binding affinity is measured by the equilibrium dissociation constant (K) with the hCD36 polypeptide of SEQ ID NO: 58 or 59 D ) to measure; (b) The antibody was expressed at 1×10 -8 M or less, 1×10 -9 M or less, 1×10 -10 M or less binding affinity to mouse CD36; optionally, wherein the binding affinity is measured by the equilibrium dissociation constant (K) with the mCD36 polypeptide of SEQ ID NO: 60 or 61 D ) to measure; (c) The antibody was expressed at 1×10 -8 M or less, 1×10 -9 M or less, 1×10 -10 M or less binding affinity to rhesus monkey CD36; optionally, wherein the binding affinity is measured by the equilibrium dissociation constant (K) with the rhesus monkey CD36 polypeptide of SEQ ID NO: 62 or 63 D ) to measure; (d) the antibody inhibits CD36-dependent oxidized LDL uptake in F293 cells overexpressing surface human CD36 by at least 65%, at least 75%, at least 85%, at least 95% or at least 100%; optionally, wherein at a concentration of oxLDL of 1-10 μg / mL, the antibody has an IC of 5 nM or less, 1 nM or less, 0.5 nM or less, or 0.1 nM or less 50 ; (e) the antibody inhibits CD36-dependent oxidized LDL uptake in U937 cells by at least 65%, at least 75%, at least 85%, at least 95% or at least 100%; optionally, wherein at a concentration of oxLDL of 1-10 μg / mL, the antibody has an IC of 5 nM or less, 1 nM or less, 0.5 nM or less, or 0.1 nM or less 50 ; and / or (f) the antibody inhibits CD36-dependent oxidized LDL uptake in mouse CD45+ TIL by at least 65%, at least 75%, at least 85%, at least 95% or at least 100%; optionally, wherein at a concentration of oxLDL of 1-10 μg / mL, the antibody has an IC of 5 nM or less, 1 nM or less, 0.5 nM or less, or 0.1 nM or less 50 .
11. An isolated polynucleotide or vector comprising a sequence encoding a polypeptide of the anti-CD36 antibody according to any one of claims 1-10.
12. The isolated polynucleotide or vector of claim 11, wherein the polypeptide comprises an amino acid sequence comprising: (a) CDR-H1 comprises the amino acid sequence of SEQ ID NO: 3, 21, 24 or 27; CDR-H2 comprises the amino acid sequence of SEQ ID NO: 4, 28, 31, 34, 37, 40 or 43; and CDR-H3 comprises the amino acid sequence of SEQ ID NO: 5; (b) CDR-L1 comprises an amino acid sequence selected from SEQ ID NO: 7; CDR-L2 comprises an amino acid sequence selected from SEQ ID NO: 8, 12 or 15; and CDR-L3 comprises an amino acid sequence selected from SEQ ID NO: 9, 13 or 18; (c) a heavy chain variable domain (V) having at least 90% identity to a sequence selected from SEQ ID NO: 2, 20, 23, 26, 30, 33, 36, 39 or 42. H ) amino acid sequence; (d) a light chain variable domain (V) having at least 90% identity to a sequence selected from SEQ ID NO: 6, 11, 14 or 17 L ) amino acid sequence; (e) a heavy chain (HC) amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NO: 44, 48, 50, 51, 52, 53, 54, 55, 56 or 57; and / or (f) a light chain (LC) amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NO: 45, 46, 47 or 49.
13. An isolated host cell comprising a polynucleotide or a vector according to any one of claims 11-12; optionally, wherein the host cell is selected from Chinese hamster ovary (CHO) cells, myeloma cells (e.g., Y0, NS0, Sp2 / 0), monkey kidney cells (COS-7), human embryonic kidney cell line (293), baby hamster kidney cells (BHK), mouse Sertoli cells (e.g., TM4), African green monkey kidney cells (VERO-76), human cervical cancer cells (HELA), canine kidney cells, human lung cells (W138), human liver cells (Hep G2), mouse mammary tumor cells, TR1 cells, Medical Research Council 5 (MRC 5) cells and FS4 cells.
14. A method for producing an antibody, comprising culturing the host cell according to claim 13, thereby producing the antibody.
15. A pharmaceutical composition comprising the antibody according to any one of claims 1 to 10 and a pharmaceutically acceptable carrier.
16. The composition of claim 15, wherein the composition further comprises a chemotherapeutic agent.
17. A composition according to claim 15, wherein the composition further comprises an antibody specific for an immune checkpoint molecule; optionally, wherein the immune checkpoint molecule is selected from PD1, PD-L1, LAG3, CTLA-4, A2AR, TIM-3, BTLA, CD276, CD328, VTCN1, IDO, KIR, NOX2, VISTA, OX40, CD27, CD28, CD40, CD122, CD137, GITR, ICOS.
18. The composition of claim 15, wherein the composition further comprises an immunostimulatory cytokine; optionally, wherein the immunostimulatory cytokine is selected from IL-2, IL-7, IL-10, IL-12, IL-15, IL-21 and IFN-α.
19. A method for treating a CD36-mediated disease in a subject, the method comprising administering to the subject a therapeutically effective amount of an antibody according to any one of claims 1-10, or administering to the subject a therapeutically effective amount of a pharmaceutical composition according to any one of claims 15-18; optionally, wherein the disease is cancer; optionally, wherein the cancer is colon cancer, pancreatic cancer, ovarian cancer, HCC, renal cancer, breast cancer, lung cancer, gastric cancer, melanoma, head and neck cancer, or oral cancer.
20. The method of claim 19, wherein the cancer is colon cancer, pancreatic cancer, ovarian cancer, HCC, kidney cancer, breast cancer, lung cancer, gastric cancer, melanoma, head and neck cancer, or oral cancer.
Citation Information
Patent Citations
Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof
EP0404097A2
Process for purifying antibody
US20020164328A1
Antibody composition-producing cell
US20030115614A1
Glycoprotein compositions
US20030157108A1
Antibody composition which specifically binds to CD20
US20040093621A1
